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General Introduction
1Introduction
Epidemiology
Melanoma, while responsible for a minority of all new skin cancers, is certainly the most 
lethal, accounting for 90% of skin cancer associated deaths1. Incidence of this deadly 
disease has risen in the past decades, both on a global level2, 3 , and on a national level4, 5. 
In the Netherlands, the number of newly diagnosed melanomas increased from 2,593 
in 2005 to 5,926 in 20156, and the number of melanoma related deaths increased from 
624 to 826 in the same time span. Globally, 230,000 melanomas were diagnosed and 
55,489 melanoma related deaths occurred in 2012 7, 8. Melanoma incidence and mortal-
ity world adjusted standardized rates (WSR) in the Netherlands were the second highest 
of Western Europe8: in 2014 national incidence was 20.6/100,000 WSR, and mortality was 
2.5/100,000 WSR4. 
Several attributable factors have been identifi ed such as ultraviolet (UV) radiation 
and increased sun exposure in fair skin phenotypes, and a history of sunburn (as a 
child)9, but still much is unknown about the development and progression of cutaneous 
melanoma, as not all melanomas are UV-radiation induced10. Classifi cation systems have 
been brought into life to aid in stratifying patients according to their prognosis: which 
is currently accurately defi ned in the TNM melanoma staging system by the American 
Joint Committee on Cancer (AJCC) 11. 
(History of) Nodal Staging
For melanomas with a Breslow thickness of >1mm (or <1mm but presence of high 
risk features such as ulceration, high level of Clark invasion or a high mitotic rate), the 
risk of nodal metastases is substantial, warranting adequate nodal staging1, 11-13. Nodal 
status is one of the most powerful prognostic factors for primary melanomas with clini-
cally negative nodes11, 14. Determination of nodal status is ideally performed based on 
histopathological proof of melanoma metastases in lymph node tissue, as physical 
examination and imaging techniques alone are not accurate enough15-17. Traditionally, 
elective lymph node dissections were carried out in order to determine nodal status, 
acquire adequate locoregional control, and potentially improve survival3, 18. While in 
theory a promising method, trial results turned out to be negative; there was absolutely 
no survival benefi t for patients undergoing elective lymph node dissection compared to 
patients who received nodal observation only, albeit that some studies suggested ben-
efi ts for subgroups19-24. Meanwhile, the morbidity of an elective lymph node dissection 
was substantial, consisting of prolonged wound infections, seroma and development 
of chronic lymph edema. As only around 20% of all patients undergoing elective lymph 
node dissection have positive nodes, a more elegant way was sought to identify these 
patients with poor prognosis. This led to the introduction of the lymphatic mapping 
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technique for sentinel node biopsy by Morton et al25. In short, this technique consists 
of preoperative lymphoscintigraphy with Tc99-colloid, dermal injection of patent blue 
around the melanoma scar, and perioperative use of a handheld gamma-probe Geiger 
teller to localize the sentinel node(s)25, 26. The concept of the sentinel node was based on 
the hypothesis that melanoma cells spread from the primary tumor site to the sentinel 
node prior to reaching adjacent lymph nodes in the same regional lymph node basin. In 
case of lymphatic metastasis the sentinel node will be affected first, acting as a barrier. 
If the sentinel node is negative, adjacent lymph nodes are unlikely to be affected25, 27-29. 
SNB and CLND
Since then, it has proven its staging value unequivocally11, 30, 31, but its therapeutic value 
is still under debate. To date no prospective trial has demonstrated evidence of a clear 
survival benefit due to sentinel node biopsy. The largest international multicenter clinical 
randomized trial investigating wide local excision and sentinel node biopsy versus wide 
local excision and nodal observation, the MSLT1, did not show a difference in melanoma 
specific (MSS) survival, primary endpoint of the trial for all included patients30. These 
results support the alternative hypothesis that melanoma spreads simultaneously to 
lymph nodes and distant sites, rendering the sentinel node as an indicator of metastatic 
spread instead of a barrier.
Ideally, nodal status is to be determined in a non-invasive manner, especially when 
regarding the lack of evidence proving a therapeutic effect. Ultrasound of clinically non-
suspicious lymph node regions is a procedure which has been investigated extensively, 
and while proven to be effective in reducing the number of SNBs for breast cancer32, 
results for melanoma remain variable at best16, 33, 34. Voit et al. showed that in highly 
dedicated hands a fair sensitivity and specificity could be reached35, 36, but these results 
remain to be reproduced in a multicenter setting.
Since the therapeutic value of SNB remains to be proven, any additional value of 
completion lymphadenectomy is likely to be limited. While results of the MSLT 2 trial37 
randomizing between CLND and nodal observation only after a positive SN are to be 
awaited, the DeCOG trial by Leiter et al. with a similar trial design, did not show any 
distant metastasis free survival difference at 3-years follow-up38. Full accrual was not 
reached due to a lower than expected inclusion rate, and the majority of patients had a 
small SN tumor burden, but the fact that there was absolutely no difference in survival 
renders the hypothesis that CLND is therapeutic more unlikely.
Then why perform a SNB and CLND at all? To date, the SNB remains the most powerful 
nodal staging tool for melanoma, which is highly valuable in informing patients and 
their treating physicians on prognosis11, 30. 
After decades of conducting randomized clinical trials, effective immunotherapies 
such as ipilimumab (CTLA4 inhibitor)39-41 and nivolumab/pembrolizumab (anti-PD1)42-44 
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1fi nally have become a game changer for advanced melanoma (i.e. irresectable stage III 
and stage IV patients). Their effi  cacy in prolonging recurrence free survival and poten-
tially even melanoma specifi c survival is shown) 39-41, 43-45. This is of great value to stage III 
patients too; as these therapies have the potential to be eff ective in adjuvant setting as 
well46. Past adjuvant trials mainly were negative; for instance the EORTC 18991 trial with 
(peg-) interferon-alpha versus placebo, which only showed a potential reduced hazard 
ratio for ulcerated primaries47 and the Sunbelt Melanoma Trial with high-dose interferon 
alpha-2b with no survival diff erences48. Primary results from the EORTC 18071 (adjuvant 
ipilimumab versus placebo) trial49 are promising, showing 11% overall survival benefi t 
for patients treated with ipilimumab at a dose of 10mg/kg, and also a reduced hazard 
ratio for recurrence free survival, in particular for microscopic stage III (i.e. SN positive 
patients)50. This has put adjuvant melanoma treatment into a whole new perspective. 
Since trials like these require adequate nodal staging with SNB and CLND in case of a 
positive SN as a major inclusion criterion 49, 51, SNB and CLND remain worthwhile for now. 
Therapeutic LND
Clinically evident lymph node metastases require a whole diff erent approach, as regional 
control and quality of life become equally important to staging. Regional control is often 
best reached with radical surgery, but the extent of surgery is not always well defi ned. 
Lymph node dissections in the groin area are of particular interest with regards to this 
aspect; as these are typically divided into superfi cial (inguinal + femoral lymph nodes) 
and combined superfi cial and deep (deep inguinal, iliac, obturator lymph nodes) dis-
sections52. There is clear evidence that pelvic lymph node metastases (iliac or obturator 
level) are associated with poor survival53-56. As a groin dissection is a morbid procedure, 
associated with wound infections and development of chronic lymph edema57-59, proper 
patient selection is necessary. Historic cohorts show contradicting results on the po-
tential association between extent of surgery and survival 53, 60-62. One of the possible 
options to minimize the number of patients whom undergo a combined groin dissec-
tion and have negative pelvic nodes is to follow a two-step approach. Identifi cation of 
patients with a low suspicion of pelvic lymphadenopathy based on preoperative CT- or 
PET-CT imaging, may prevent these patients from undergoing iliac lymphadenectomy 
if the pathology results of a superfi cial groin dissection are in line with these fi ndings. 
While this approach does not diminish the number of patients at risk for morbidity to 
zero, this may reduce the number of negative pelvic dissections. 
Ultimately, as is the case for patients undergoing CLND, therapeutic lymph node dis-
sections may be reserved as a fi nal resource in case of failed adjuvant therapy. In short, 
now is the time to reassess the need for an aggressive surgical approach, and perhaps to 
start to convince ourselves that “less is more”.
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Outline of This Thesis
Part I – Nodal Staging
Part I of this thesis investigates whether nodal staging of the clinically node negative 
melanoma patient can be performed using less invasive alternatives, and whether the 
indication for nodal staging in thin melanomas is justified. In Chapter 2 the national 
thin (pT1) melanoma population is examined according to substaging: both the 6th AJCC 
staging edition and the 7th edition to see whether “high risk” thin melanomas are identi-
fied and stratified more accurately. Secondly the effects of the implementation of the 2nd 
version of the Dutch Melanoma Guideline are visualized including the recommendation 
to consider a sentinel node biopsy (and thus nodal staging) for pT1b melanomas. In 
Chapter 3 ultrasound morphology criteria of the sentinel node, more specific the “echo 
free island”, are discussed, developed to improve accuracy of ultrasound and fine needle 
aspiration cytology (FNCAC) techniques in clinically node negative melanomas. The 
“echo free island” may serve as an early sign of micrometastasis in the sentinel node, 
which should raise suspicion in the ultrasonographist. In Chapter 4 the long-term re-
sults of ultrasound and FNAC of the sentinel node are presented. The Berlin ultrasound 
morphology criteria, primarily designed to assess the sentinel node for presence of 
micrometastases, warranting FNAC for confirmation, might be of prognostic value. 
Chapter 5 gives an overview of the current evidence on ultrasound of the sentinel node 
in melanoma, presents the results of a pilot study and presents the study protocol of the 
GULF trial; Gamma probe and ultrasound guided FNAC of the sentinel node, designed as 
a potential minimally invasive alternative for the surgical sentinel node biopsy. 
Alteration of the staging techniques is one way to minimalize morbidity; another is to 
reassess the indication for nodal staging. 
Part II – Timing of Surgery
Part II focuses on the timing of nodal staging. Time is of the essence in current oncology 
practice, but the maximum referral times and wait-list times posed by national mela-
noma guidelines are not based on solid evidence. In a highly stressed referral system, a 
delicate balance between urgent referrals and minimization of long wait-lists is needed, 
as otherwise the value of a true high urgency referral is lost, which potentially negatively 
affects prognosis of patients who do need treatment as soon as possible. In Chapter 6 
the timing of sentinel node biopsy is investigated in sentinel node positive patients, as 
they are most likely to benefit from early removal of positive lymph nodes. Chapter 7 
includes both sentinel node positive and negative patients, as timing of sentinel node 
biopsy may affect the sentinel node positivity rate as well as survival outcome. In Chap-
ter 8 the timing of completion lymphadenectomy is investigated, as removal of any ad-
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1ditional positive lymph nodes may potentially be the last therapeutic procedure. Should 
it be performed within a certain amount of time? Is there a window of opportunity?
Part III – Extent of Groin Dissections
The fi nal part of this thesis focuses on the extent of surgery, in particular the extent 
of groin lymph node dissection. There is clear evidence that presence of pelvic lymph 
node metastases (iliac or obturator level) is associated with poor survival. By correctly 
identifying these patients prior to iliac lymphadenectomy, which is a morbid procedure, 
patients without pelvic lymph node metastases can be spared the pelvic part of a groin 
dissection. Chapter 9 presents a possible two-step approach for melanoma patients 
with palpable groin metastases and no suspicious preoperative imaging (CT or PET/
CT) who are scheduled for superfi cial groin dissection (inguinal lymph nodes only) or 
combined superfi cial and deep groin dissection (inguinal and iliac lymph nodes). 
Chapter 1
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Abstract
Objective Unlike breast and thyroid cancer, the use of Ultrasound (US) guided Fine 
Needle Aspiration Cytology (FNAC) for preoperative staging is limited in melanoma. 
New US morphology criteria have shown that US-FNAC can correctly identify 50% of all 
involved sentinel nodes (SN) in melanoma patients prior to surgical excision. Aim of this 
study was to examine a new criterion, the Echo-Free Island (EFI).
Methods 1,000 consecutively staged melanoma patients (Breslow thickness > 1mm 
or < 1mm, but ulcerated, Clark IV/V or regressed) scheduled for SN staging underwent 
preoperative US. US morphology items were assessed: Peripheral Perfusion (PP), Loss of 
Central Echoes (LCE), Balloon Shape (BS) and EFI. FNAC was performed in case of suspi-
cious and malignant US patterns. All patients proceeded to undergo an SN biopsy or 
direct CLND (in case of positive FNAC). 
Results 7% was male. Mean / median Breslow thickness was 2.58 / 1.57 mm. Mean / 
median follow-up was 56 / 53 months. SN was positive in 21%. EFI information was 
available in 95.3%. It was seen in 40 patients (4%). EFI sensitivity was 10.8%, specificity 
97.6%, PPV 50% and NPV 80.2%. EFI was significantly correlated to PP (67.5%). There was 
no correlation to BS or LCE. 5-year MSS of patients with EFI was significantly worse: 80% 
versus 92% when absent.
Conclusions The Echo-Free Island (EFI) can be useful in the early detection of SN mela-
noma metastasis. It is an early sign of involvement and thus associated with a decreased 
survival.
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Introduction
Unlike staging for breast or thyroid cancer, preoperative ultrasound (US) of the regional 
sentinel nodes (SNs) is not routinely performed for melanoma1-4. Previously, our experi-
ence with preoperative US guided fi ne needle aspiration cytology (FNAC) for the early 
detection of SN involvement in melanoma was described5-7. Amongst others, the pattern 
of an echo free island (EFI) was presented. Other morphologic factors, such as peripheral 
perfusion (PP), balloon shaped (BS) lymph node and loss of central echoes (LCE) were 
key characteristics in these fi rst analyses. EFI was a relatively infrequent fi nding. With 
increased experience, the discriminative role of this US morphologic characteristic has 
now been investigated.
In a 2011 meta-analysis Catalano et al.8 found that 31 out of 201 articles matched their 
inclusion criteria to provide a description of the use of US scanning for the detection of 
melanoma lymph node metastases. This compilation of articles showed that, in contrast 
to older systems, modern high-resolution scanners now allow for recognition of very 
subtle abnormalities within the lymph node. Predictive criteria should therefore be 
modifi ed according to the improved devices and resolution.
Especially the color Doppler imaging should be seen diff erently nowadays. Even if 
set adequately for detecting slow fl ow, the scanners used in the past would frequently 
not have been able to allow for the recognition of relevant signals in malignant lymph 
nodes, simply because of the low intrinsic sensitivity of those machines8. Instead, modern 
equipment would be very sensitive to slow fl ow and optimal depiction of the abnormal 
angiographic architecture of superfi cial lymph node metastases8. The previous limita-
tions of Doppler systems would help explain why many authors did not consider color 
Doppler fi ndings in their assessment of melanoma lymph node metastases in the past8. 
Unfortunately though, all meta-analyses comprise a certain time-period, and Catalano 
et al. used the years 1989 – 20098. Our pivotal papers from 2009-2010 and obviously 
the most recent from 2014, reporting the largest prospective collected database on 
melanoma lymph node US patterns, were not used in the meta-analysis5-7. In this large 
database up to 65% of all metastases could be potentially identifi ed preoperatively5. 
The most sensitive morphologic criterion was PP, which could potentially identify 77% 
of metastases preoperatively, but had a low specifi city of 52%6. BS and LCE had a lower 
sensitivity, but a high positive predictive value (PPV) of 96% and 65%, respectively6. 
Moreover, a clear correlation between these US patterns and SN tumor burden could 
be established. Smaller lesions showed PP, whereas only in advanced lesions BS and LCE 
was seen5. 
Aim of the current study was to report on the infrequently observed morphologic 
criterion, the echo free island (EFI), which often indicates presence of micrometastatic 
involvement of the lymph node in melanoma patients.
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Patients and Methods
Patients
This prospective database included all patients presenting with a newly diagnosed, 
histopathologically proven, primary malignant melanoma (at least 1.00 mm Breslow 
thickness, or if less, at least Clark level IV/V, ulcerated and/or with regression) and who 
were planned for an SN procedure at the department of dermatology, Charité, Univer-
sity Medicine Berlin, Germany. The institutional ethical review board (ERB) approved 
the study and informed consent was obtained from all patients enrolled. For the cur-
rent analyses of the US patterns, inclusion was halted after the first 1,000 consecutive 
patients with sufficient follow-up (July 2001 – November 2010). Results in the first 400 
patients and the follow-up in the first 1,000 patients have been previously reported5-7.
Methods
The US patterns were examined, determined and listed in a prospective database. 
All patients were scheduled for an SN procedure in either a 1 or 2 day protocol. In all 
cases, patients first underwent a lymphoscintigraphy, which allowed for a targeted US 
examination of the SNs and adjacent lymph nodes. In the timeslot between lymphos-
cintigraphy and surgery, patients were examined by US in B-Mode and Power Doppler. 
US was aimed at clearly depicting the location of the suspected SN and at clearly stating 
whether it seemed involved or not. If US depicted a suspicious or malignant SN, FNAC 
was performed for verification of the lesion (3-4 repeat FNACs were performed within 
one single procedure). If a clearly malignant US pattern could not be verified by FNAC, 
patients proceeded to undergo an SN nevertheless, since the decision to alter a planned 
SN directly into a CLND was always based on positive cytology.
Micro-anatomic location of the SN metastases was evaluated according to the criteria 
by Dewar et al.9. SN tumor burden was assessed according to the Rotterdam Criteria for 
SN tumor burden10-12. 
Ultrasound Technique and Image Analysis
All US examinations were performed using the high-end device MyLab 70 (ESAOTE, 
Genova, Italy) equipped with 3 transducers (1-18 MHz) (B-mode, 30 pictures per second, 
color Doppler, Power Mode). The lymph node was measured, the pattern was described 
and it was classified as benign [b], suspicious [s] or malignant [m].
In general, an US was considered suspicious, when PP was present or if the central 
echo was wandering towards the rim. US was considered malignant if there was a total 
LCE or if the lymph node was enlarged and BS. If an echo-poor disruption of the lymph 
node architecture was seen, the lymph node was described as EFI (Figure 1). Details of 
these Berlin US morphology criteria have been reported previously elsewhere6.
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Fine Needle Aspiration Cytology (FNAC) in detail
FNAC was performed with a hand-held Binder-valve as described in detail elsewhere5. 
The fi ne needle used for superfi cial lymph nodes has a diameter of approximately 0.4 
mm (26G), especially for small targets. A smear was considered technically suffi  cient, if it 
contained approximately 100 cells.
Cytology results were reported to the surgeons and it was left to their discretion how 
to proceed with surgery, either SN or LND. If the US did not show any suspicious (EFI, PP) 
or malignant (BS, LCE) patterns or if the cytology was negative, the patient proceeded to 
undergo the scheduled SN.
Histopathological evaluation of excised SN 
In brief, the EORTC Melanoma Group protocol according to Cook et al. was followed13. 
Lymph nodes were fi xed for 24 hours in buff ered formalin. After fi xation they were cut 
in half through the hilum and its longest dimension, and embedded in paraffi  n. In rare 
cases, exceptionally larges lymph nodes were sectioned parallel to the fi rst cut in order 
to fi t into the blocks. Fiver serial step sections of 4 μm each were cut from each face 
of the lymph node and staining with H&E, S100 and HMB-45 was performed. Micro-
anatomic location of the metastases and SN tumor burden were assessed according to 
the Dewar and Rotterdam Criteria, respectively9-12. 
Figure 1. Illustration of the Echo-Free Island (EFI) Phenomenon on Ultrasound Examination.
Line 1 and 2 indicate the maximum diameters of the lymph node, line 3 and 4 indicate the
maximum diameters of the EFI within the lymph node. 
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Statistics
To assess the predictive value of individual and combination of US patterns for involved 
SNs; sensitivity, specificity, PPV (Positive Predictive Value) and NPV (Negative Predictive 
Value) were calculated. Associations were tested with Pearson’s chi square test. Disease-
Free Survival (DFS) and Melanoma Specific Survival (MSS) were calculated for SN date 
until recurrence (DFS) or death due to melanoma (MSS). Patients were censored at the 
date of last known follow-up if no events had taken place. Univariate analyses of survival 
were performed using the Kaplan-Meier method and log-rank test. Multivariate analyses 
to determine the prognostic value of covariates regarding survival were performed us-
ing the Cox’s proportional hazard model. Statistical analyses were all performed with 
Stata®, version 10.0 (Stata Corporation, College Station, TX, USA). P values of less than 
0.05 were considered as significant.
Results
Table 1 summarizes the most important patient, primary tumor, SN and US characteris-
tics. Mean and median follow-up of all 1,000 patients was 56 and 53 months, respectively. 
The EFI pattern could be assessed in 953 patients (95.3%), the pattern was present in 40 
patients (4%).
EFI showed a sensitivity of 10.8% for metastasis in the final histology of the SN. 
Specificity was high (97.6%), PPV was 50%, NPV was 80.2% (Table 2). Moreover, a clear 
correlation was seen with PP. In 27/40 cases with EFI, PP was also seen (67.5%) (Table 2). 
However, in case of PP, the EFI was only seen in a minority of cases 27/273 (9.9%). There 
was no correlation between EFI and BS (P=0.852) (Table 2). In most cases, when an EFI 
was seen, the central echo would still be normally present 24/40 (60%) (Table 2).
Univariate analysis showed that patients with an EFI had a significantly worse 5-year 
MSS compared to patients without the EFI US pattern (80% vs. 92%) (P<0.001)(Figure 2). 
The univariate hazard ratio (HR) for MSS was 3.32 (95% CI 1.66 – 6.68) (P=0.001).
Multivariate analysis for MSS demonstrated that EFI was non-significant when ana-
lyzed together with other known independent prognostic factors (ulceration, Breslow 
thickness and PP, data not presented). 
When the multivariate analysis for MSS was performed separately for US patterns only, 
the presence of any of these patterns was associated with a detrimental survival. EFI 
had a HR of 2.06 (95% CI 1.01 – 4.20) (P=0.048). BS had a HR of 2.62 (95% CI 1.01 – 6.79) 
(P=0.048). LCE has a HR of 3.05 (95% CI 1.26 – 7.40) (P=0.013). PP was associated with a 
HR of 2.57 (95% CI 1.49 – 4.41) (P<0.001).
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Discussion
The fi nal results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1) have 
been published14. Although the MSLT-1 trial did not demonstrate a signifi cant benefi t 
for wide local excision (WLE) + SN staging (in case of a positive result followed by CLND) 
versus WLE + sequential nodal observation, the authors concluded that biopsy-man-
agement prolongs DFS for all patients and prolongs DMFS and MSS for node positive 
Table 1. Baseline Patient, Primary Tumor, Sentinel Node and Ultrasound Characteristics of All 1,000 Pa-
tients
Characteristic N % Characteristic N %
Gender SN Tumor Burden 
(n = 208)
Male 567 57% ≤ 0.1 mm 30 14%
Female 433 43% 0.1 – 1.0 mm 62 30%
Histological subtype > 1.0 mm 62 30%
SSM 595 60% LND / Unknown 54 26%
NM 242 24% PP
LMM 37 4% Absent 663 66%
ALM 44 4% Present 273 27%
Unknown / other 82 8% Unknown 64 7%
Breslow Thickness LCE
Mean / Median (Range) 2.58 / 1.57 (0.2 – 44) mm Central Echo Present (Normal) 791 79%
T1 (≤ 1.00 mm) 288 29% Wandering to Rim 97 10%
T2 (1.01 – 2.00 mm) 308 31% Lost 66 6%
T3 (2.01 – 4.00 mm) 231 23% Unknown 46 5%
T4 (> 4.00 mm) 173 17% BS
Ulceration Absent 881 88%
Absent 758 76% Present 53 5%
Present 242 24% Unknown 66 7%
SNs Removed EFI
Mean / Median 1.72 / 1 (1 – 13) Absent 913 91%
SN result Present 40 4%
Negative 792 79% Unknown 47 5%
Positive 208 21% US-FNAC Result
Direct LND (after + FNAC) 43 4% Not Performed & Negative 892 / 342 89% / 34%
43 / 208 21% Positive 98 / 342 10% / 26%
SN, sentinel node; SSM, superfi cial spreading melanoma; LND, lymph node dissection; NM, nodular mela-
noma; LMM, lentigo maligna melanoma; ALM, acrolentiginous melanoma; PP, peripheral perfusion; LCE, 
loss of central echo; BS, balloon shape; EFI, echo-free island; US-FNAC, ultrasound – fi ne needle aspiration 
cytology
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Table 2. Sensitivity, Specificity, PPV and NPV of the Echo-Free Island (EFI) and Correlation to Peripheral 
Perfusion (PP), Loss of Central Echoes (LCE) and Balloon Shape (BS)
SN negative SN positive P-value
EFI absent 732 181
EFI present 18 22 P<0.001
Correlations PP absent PP present
EFI absent 650 246
EFI present 13 27 <0.001
BS absent BS present
EFI absent 843 51
EFI present 38 2 0.851
Central Echo Wandering to Rim LCE P-Value
EFI absent 766 86 61
EFI present 24 11 5 <0.001
Central Echo / Wandering to Rim LCE
EFI absent 852 61
EFI present 35 5 0.156
SN, sentinel node; EFI, echo-free island; PP, peripheral perfusion; BS, balloon shape; LCE, loss of central echo
Figure 2. Kaplan-Meier 5-year Melanoma Specific Survival (MSS) for Patients With or Without Echo-Free 
Island (EFI)
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patients with intermediate thickness melanoma14. These last conclusions are very much 
topic of an ongoing debate15-17.
Perhaps more important is the fact that the SN biopsy provides accurate and important 
staging information14, 15. This SN result provides information on the chance of additional 
non-SN involvement of the CLND and with respect to survival. SN tumor burden further 
stratifi es these risk assessments10, 12. Nowadays, patients with signifi cant SN tumor 
burden (> 1 mm in maximum diameter), who have a high risk for relapse, might be 
eligible for adjuvant therapy (studies). Recently, the fi rst positive results with respect to 
an improved RFS have been reported for patients undergoing adjuvant Ipilimumab18, 19.
Even if SN staging itself does not provide a survival benefi t to the individual patient, 
eff ective adjuvant therapy might. Moreover, patients should be adequately staged to 
be eligible for participation into new adjuvant therapy trials. It would be unethical to 
withhold them this possibility. 
When comparing the situation in melanoma to that of breast or thyroid cancer, the 
role of US staging has been minimal. US-guided-FNAC is even less invasive than surgical 
SN staging. Previous results have shown that US-guided-FNAC can correctly identify 50% 
up to 80% in selected subgroups, of all SN metastases, prior to the surgical excision by 
SN biopsy5, 6. Important aspects to achieve these improved results are the use of newly 
defi ned US patterns and a low threshold for FNAC7.
The current paper is an addendum to the previously reported Berlin morphology 
patterns. Another potential useful item is presented, the EFI. Although the EFI is a rare 
phenomenon, the EFI is signifi cantly associated with PP in 67.5% of cases, and at the 
same time the Central Echo is still present in the majority of cases (60%), indicating 
that it is an early sign of disruption by a developing metastasis. This is illustrated by the 
survival curves, which show that EFI is associated with a signifi cantly decreased MSS. 
As these US morphologic signs can be used to detect early (sub) micrometastases in 
SNs, standard US of the lymph node basins prior to surgery may once more be consid-
ered. Ultimately, further improvement of the technique of US scanning and targeted 
FNAC of the SN may even replace the surgical SN procedure as the routine staging of 
new stage I/II melanoma patients. Currently ongoing research is being performed to 
investigate minimally invasive alternatives to the surgical SN procedure (Dutch trial: 
Gamma Probe and Ultrasound Guided Fine Needle Aspiration Cytology of the Sentinel 
Node - GULF trial, NL52091.078.15). 
In conclusion, the Echo-Free Island (EFI) as an US morphologic sign can be useful in 
the early detection of SN metastases in melanoma patients. It is an early sign of involve-
ment and thus associated with a decreased survival.
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Abstract
Background US-FNAC is a common diagnostic tool in the work-up of many cancers. 
Results in melanoma were initially poor (sensitivity 20-40%). Introduction of the Berlin 
Morphology criteria has shown potential improvement up to 65–80% in selected pa-
tients. 
Aim This cohort study evaluates the long-term survival outcome of melanoma patients 
undergoing Ultrasound (US) guided Fine Needle Aspiration Cytology (FNAC) prior to 
sentinel node biopsy (SNB) or direct lymphadenectomy.
Methods from 2001-2010 over 1,000 consecutive melanoma patients prospectively un-
derwent targeted US-FNAC prior to SNB. The Berlin US morphology criteria: peripheral 
perfusion (PP), loss of central echoes (LCE) and balloon shape (BS) were registered. FNAC 
was performed if any factor was present. All patients underwent SNB or lymphadenec-
tomy in case of positive FNAC. 
Results Median follow-up was 61 months (IQR 40-95). SN positivity rate was 21%. 
Survival analyses demonstrated that patients with positive US-FNAC had poor survival. 
After adjustment for SN status and other known prognostic features, patients with posi-
tive US-FNAC (hazard ratio (HR) 1.80, 95% CI 1.10-2.96) had worse survival than patients 
with normal US (reference). Patients with suspicious US and negative FNAC (HR 1.13, 
95% CI 0.71-1.78) had survival comparable to patients with normal US. 
Conclusions The long-term US-FNAC results support this step-wise approach to mela-
noma patients. Patients with positive US-FNAC have a poor survival and can be spared 
a SNB. Patients with suspicious US and negative FNAC should undergo SNB to detect 
microscopic occult disease. Completely US-FNAC negative patients might only require 
follow-up and no SN staging at all. 
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Introduction
Primary cutaneous melanoma used to be treated with aggressive surgery in absence 
of other successful treatment modalities. Elective lymphadenectomy was performed 
based on the hypothesis of sequential metastatic spread1. It aimed to potentially 
prevent metastatic spread of the disease, and to minimize the number of patients who 
would develop aggressive regional disease burden1. This prophylactic procedure came 
with a cost: only a minority of patients had involved lymph nodes at the time of surgery, 
a signifi cant amount of patients suff ered from long-term morbidity, and survival was 
not altered2. Morton et al. introduced a more sophisticated manner to identify those 
patients with regional nodal involvement; the sentinel node biopsy (SNB) 3. 
To date, SNB remains the gold standard for adequate staging of the N-status in clini-
cally node negative melanoma patients 4-6. Meanwhile, its therapeutic power continues 
to be topic of debate. As the fi nal trial report of the MSLT 1 did not fi nd an overall survival 
benefi t for melanoma patients undergoing wide local excision (WLE) + SNB versus WLE 
only and nodal observation7, the search for less invasive diagnostic staging methods 
continues to be worthwhile.
Early diagnosis of regional nodal involvement is important not only for adequate 
staging, but also for potential participation in adjuvant therapy trials. Adjuvant therapy 
may be of a potential greater benefi t in early stage III (SN-positive patients) compared 
to patients with palpable stage III disease. Stratifi cation by stage III (N1: SN positive) vs 
Stage III (N2: palpable nodal disease) was performed in the two largest adjuvant IFN tri-
als EORTC 18952 and 18991 demonstrated a signifi cantly greater benefi t in SN-positive 
patients 8-12. Recently a recurrence free survival benefi t for SN-positive patients was also 
demonstrated in the EORTC 18071 trial regarding adjuvant ipilimumab in stage III pa-
tients 13. The ongoing EORTC 1325 trial regarding adjuvant pembrolizumab is stratifi ed 
similarly 14. Final results regarding recurrence free survival and overall survival will have 
to be awaited for these trials, but results of the EORTC 18071 are promising. 
 Ultrasound (US) guided Fine Needle Aspiration Cytology (FNAC) is a common diag-
nostic tool proven to be helpful in the work-up of breast cancer and thyroid cancer 15, 16. 
The results of diagnostic preoperative US of the regional lymph node basins in mela-
noma patients were poor in the past decades, with a reported sensitivity of only 5 - 40% 
17-21. Hence preoperative US in combination with FNAC has not yet been adopted as a 
standard preoperative diagnostic tool. 
Previously, our group has demonstrated that is it possible to identify the sentinel node 
(SN) using targeted US with a good accuracy 22. Several others have performed targeted 
US of the SN area directly after lymphoscintigraphy as well 21, 23, 24. Correct identifi cation 
of tumor positive SNs prior to surgery is the ultimate goal of targeted US; results vary 
but can be promising when this technique is further improved. Marone et al correctly 
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identified 18 out of 122 positive SNs (15%) (from 831 excised SNs in total), and Testori 
et al. correctly identified 16 out of 16 positive SNs (100%) with targeted US, but also 
had 9 false positive patients at histological analysis (false positive rate = 36% (FP/ (TP + 
FP)) 21, 24. 
In a second study by our group US-FNAC of the SN could identify up to 65% of all 
tumor positive SNs preoperatively, and additionally the Berlin morphology criteria have 
been presented, describing specific US patterns related to early involvement with which 
a high sensitivity for US-FNAC could be achieved 25, 26. 
More recently our group reported on the first 1,000 prospective melanoma patients 
who underwent US-FNAC prior to a scheduled SNB: application of the Berlin Morphol-
ogy criteria yielded a sensitivity of up to 76% in selected patients 27. 5-year estimated 
Kaplan-Meier melanoma specific survival (MSS) and disease free survival (DFS) showed 
a significant difference in survival outcomes for each US-FNAC status 27, indicating its 
potential as a prognostic indicator. 
The current study aims to evaluate the long-term survival outcomes of this now 
fully matured cohort of melanoma patients undergoing US-FNAC prior to SNB or direct 
lymphadenectomy.
Patients and Methods
Patients
The current study concerns the long-term follow-up of a previously collected cohort by 
Voit et al. published previously 27 of over 1,000 melanoma patients who underwent US-
FNAC and SNB or immediate lymph node dissection (LND) in case of positive US-FNAC. 
Briefly, the cohort consisted of over 1,000 stage I/II consecutive melanoma patients 
who prospectively underwent US-FNAC prior to Sentinel Node Biopsy (SNB) between 
2001 and 2010. All patients had a histopathologically proven malignant melanoma 
(Breslow thickness ≥1.00mm, or at least one risk factor such as Clark level IV/V, ulcer-
ation or regression) and were scheduled for a SNB at the Department of Dermatology, 
Charité, University Medicine Berlin, Germany. The institutional ethics review board (ERB) 
approved the study and informed consent was obtained from all patients enrolled. For 
the current analysis the first 1,000 consecutive patients with sufficient follow-up (July 
2001 – November 2010) were selected. A quality control of the database was carried out 
to assure maximum retrieval of any missing data from patient records at 5-year follow-
up. Two duplicate cases were excluded and 6 patients with a second primary melanoma 
requiring a second US-FNAC and SNB were censored for survival analysis. Eight consecu-
tive study patients were added to the cohort to restore a sample size of 1,000 patients 
(1,006 US-FNAC cases) for the current analyses.
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Design
All patients underwent lymphoscintigraphy prior to US-FNAC. The Berlin US morphol-
ogy criteria: Peripheral perfusion (PP), loss of central echoes (LCE) and balloon shaped 
(BS) were registered and FNAC was performed if any factor was present. If FNAC could 
not verify a clearly malignant US pattern, patients always proceeded to undergo a SNB. 
In the early phase of the study all patients proceeded to undergo a SNB even if FNAC was 
positive (n=47). During the course of the study, a change in hospital policy allowed the 
surgeon to proceed to an immediate LND after a positive FNAC. The decision to change 
a scheduled SNB to a LND was always based on a positive FNAC. 
Defi nitions
US was considered malignant in case of LCE or BS. US was considered suspicious in case 
of PP or the wandering to the rim of the central echo. US-FNAC was considered positive 
if LCE or BS (with or without a FNAC verifi cation) was seen or in case of a positive FNAC.
When an echo-poor disruption of the lymph node architecture was observed this was 
described as Echo free island (EFI). Results of EFI have been described in detail previ-
ously 28.
US-FNAC technique and analysis 
The high-end US device MyLab 70 (ESAOTE, Genova, Italy) was used for all US examina-
tions. An expert ultrasonographist identifi ed the lymph node, measured it and described 
the morphologic pattern. The lymph node was classifi ed as benign, suspicious or malig-
nant according to the visualized pattern. Details of the ultrasound technique, image 
analysis using ultrasound morphology criteria and classifi cation have been described 
previously 25, 27. For FNAC a hand-held Binder-valve was used as described in detail 
previously 27. A smear had to contain at least approximately 100 cells to be considered 
technically suffi  cient. 
Details of pathologic examination of the SN have been described previously 27. SN 
tumor burden was measured according to the Rotterdam criteria 29, 30. Microanatomic 
location of SN metastases was evaluated according to the criteria by Dewar et al 31. Final 
histology of the SN or LND was considered as the gold standard. The fi rst 120 patients 
underwent both targeted US and FNAC of the SN regardless of the US classifi cation, as 
a feasibility study.
Statistics 
DFS and MSS were calculated from SN date until fi rst recurrence or death or censored 
at the date of last known follow-up, if no events had taken place. 5 year DFS and MSS 
were estimated using the Kaplan Meier method and compared using the log-rank test. 
Cox’s proportional hazard model was applied for univariable and multivariable analyses 
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to determine the prognostic value of covariates regarding MSS. Hazard ratios (HR) were 
estimated for: SN status, SN tumor burden, US-FNAC result, age, gender, primary tumor 
location, histologic subtype, Breslow thickness, and ulceration status. SN tumor burden 
was left out as covariate for the multivariate Cox regression model 1 as a significant cor-
relation with SN status could be expected, and was tested in a separate model 2 without 
SN status. All statistical analyses were performed with SPSS version 21 (IBM Corporation, 
Armonk, NY, USA). P values of less than 0.05 were considered as significant. 
Results 
Baseline features of the first 1,000 US-FNAC cases have been described previously 
elsewhere 27. After quality control (where 2 duplicate cases were excluded and 6 cases 
were identified concerning patients with a second primary melanoma and a second US-
FNAC) eight consecutive study patients were added to the cohort to restore a sample 
size of 1,000 patients (1,006 cases) for the current analyses. Patient and tumor features 
are displayed in Table 1 and Table 2. Mean/median follow-up was 66/61 months (IQR 
40 - 95). 
Survival
5-year and 10-year Kaplan-Meier estimated MSS was significantly better for patients with 
negative US and FNAC: 90% (SE 1%) vs. 51% (SE 5%) for US-FNAC positive patients and 
85% (SE 2%) vs. 34% (SE 6%) respectively (both p<0.0001) (Figure 1a). This difference in 
MSS remained significant in the group of SN positive patients: 5-year MSS 71% (SE 5 %) 
for US-FNAC negative patients vs. 51% (SE 5 %) for US-FNAC positive patients and 10-
year MSS 65% (SE 7%) vs. 33% (SE 6%) (both p<0.0001) respectively (Figure 1b). Since 
there was only 1 SN negative patient with positive US-FNAC (whom turned out to have 
a false negative SNB), no log rank test comparison could be performed for SN negative 
patients. The corresponding 5-year and 10-year Kaplan-Meier estimated DFS rates for all 
patients were 84% (SE 3%) for US-FNAC negative patients vs. 33% (SE 5%) for US-FNAC 
positive patients, and 79% (SE 2%) vs. 24% (SE 6%) (both P<0.0001) respectively (Figure 
2). 
There were 778 both US (and/or FNAC) negative and SN negative patients. Of these 
patients, 49 (6%) developed regional lymph node metastases. False negative rate (FN/ 
(FN+TP)) was 49 / (49 + 119) = 29%. The median time interval to nodal basin failure 
was 28 months (interquartile range 19 – 44 months). The majority of these patients had 
either a NM (n=23) or a SSM (n=21, 2); 2 patients had an ALM; 1 patient a LMM; and in 2 
patients exact histology data were not available. 
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Classifi cation of patients according to Berlin ultrasound morphology criteria showed 
that patients with a suspicious US (i.e. presence of PP or beginning LCE = ‘wandering to 
the rim’) had a slightly worse 5-year MSS than patients with a normal US; and patients 
with a clearly malignant US (i.e. presence of BS or total LCE) had the poorest survival: 
5-year MSS 91% (normal US, SE 1%) vs. 81% (suspicious US, SE3%), and vs. 55% (ma-
lignant US, SE 6%), and 10-year MSS 86% (SE 2%) vs. 74% (SE 4%) and 38% (SE 8%) (all 
p<0.0001) (Figure 3). 
Table 1. Baseline characteristics of all melanomas (1,006 in 1,000 patients).
Characteristic n (%) or mean/median (range)
Gender  
Female 435 (43)
Male 571 (57)
Histological subtype  
SSM 601 (60)
NM 242 (24)
LMM 37 (4)
ALM 44 (4)
Unknown 82 (8)
T stage  
T1 (≤1.00mm) 294 (29)
T2 (1.01-2.00mm) 309 (31)
T3 (2.01-4.00mm) 233 (23)
T4 (>4.00mm) 170 (17)
Ulceration  
Absent 763 (76)
Present 243 (24)
SNs removed 1.72/1 (1-13)
SN result
Negative 797 (79)
Positive (incl. 43 direct LND for pos. FNAC) 209 (21)
immediate LND (after pos. FNAC) 43 (4) / 43/209 (21)
SN tumor burden Rotterdam criteria (n=209)
<0.1mm 32 (15)
0.1 - 1.0mm 63 (30)
>1.0mm 64 (31)
immediate LND or unknown 50 (24)
Baseline characteristics of all melanomas with n and percentage or mean/median and range. Abbrevia-
tions: US, ultrasound; SSM, superfi cial spreading melanoma; NM, nodular melanoma, LMM, lentigo maligna 
melanoma; ALM, acrolentiginous melanoma; SN, sentinel node; LND, lymph node dissection, pos., positive; 
FNAC, fi ne needle aspiration cytology.
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The unadjusted and adjusted HRs for 5 year MSS are shown in table 3. 
US-FNAC results were categorized as follows: US normal and FNAC negative; US 
suspicious and FNAC negative; US positive and/or FNAC positive. After adjustment for 
SN status, gender, age, Breslow thickness, primary tumor location, histology type, and 
ulceration in model 1, suspicious US was no prognostic indicator, but positive US-FNAC 
did remain as a prognostic indicator for worse MSS.
A second model was formed with SN tumor burden. An interaction term was calcu-
lated for SN tumor burden and US-FNAC result since they were found to be significantly 
correlated 27. In a simple model with US-FNAC result and SN tumor burden, the interac-
tion term was not significant (data not shown). The unadjusted and adjusted hazard 
ratios for 5 year MSS for model 2 are shown in table 3. In this model, US-FNAC was no 
prognostic indicator. 
Table 2. Ultrasound and Fine Needle Aspiration Cytology Results
Characteristic N(%)
PP
Absent 670 (67)
Present 273 (27)
Unknown 63 (6)
LCE
central echo present (normal) 798 (79)
central echo wandering to rim 97 (10)
central echo lost 66 (7)
Unknown 45 (5)
BS
Absent 887 (88)
Present 53 (5)
Unknown 66 (7)
US results
US benign 683 (68)
US suspect 247 (25)
US malignant 76 (7)
FNAC results n=341
benign 252 (74)
malignant 89 (26)
US/FNAC results
Normal US/ FNAC negative 681 (68)
PP at US 206 (20)
BS/LCE and/or FNAC positive 119 (12)
Ultrasound results of all 1,006 melanomas. Abbreviations: PP, peripheral perfusion; LCE, loss of central echo; 
BS, balloon shape; US, ultrasound; FNAC, fine needle aspiration cytology.
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 No. at risk 0 12 24 36 48 60 72 84 96 108 120 
US-FNAC neg 892 865 818 738 637 483 368 288 232 158 89 
US-FNAC pos 108 87 63 51 44 40 27 19 17 14 9 
A 
 No. at risk 0 12 24 36 48 60 72 84 96 108 120 
US-FNAC neg 101 93 79 71 58 43 29 23 18 11 6 
US-FNAC pos 107 86 62 50 43 39 26 18 16 13 9 
B 
Figure 1. Estimated Kaplan-Meier melanoma specifi c survival of all patients (A) and of SN positive patients 
only (B) for ultrasound (US) – fi ne needle aspiration cytology (FNAC) negative result (blue line) and for US-
FNAC positive result (red line) compared with the log-rank test. 
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no. at risk 0 12 24 36 48 60 72 84 96 108 120 
US normal 679 663 631 570 493 369 281 217 176 122 66 
US suspicious 245 230 204 179 158 128 94 77 61 45 29 
US malignant 76 59 46 40 30 26 20 13 12 5 3 
Figure 3. Estimated Kaplan-Meier melanoma specific survival of all patients for ultrasound (US) category 
normal (yellow line), suspicious (blue line) and malignant (red line) compared with the log-rank test. 
 No. at risk 0 12 24 36 48 60 72 84 96 108 120 
US-FNAC neg 892 839 771 689 585 449 332 266 213 148 80 
US-FNAC pos 108 61 40 34 30 26 19 13 13 10 7 
Figure 2. Estimated Kaplan-Meier disease free survival of all patients for ultrasound (US) – fine needle 
aspiration cytology (FNAC) negative result (blue line) and US-FNAC positive result (red line) compared with 
the log-rank test. 
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Table 3. Cox Proportional Hazards Regression Analysis for Melanoma Specifi c Survival (n=1,000)
Variable Univariable Multivariable model 1 Multivariable model 2
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
SN status
Negative Ref Ref -
Positive** 6.52 4.73-8.98 <0.0001* 3.65 2.37-5.63 <0.0001* -
SN tumor burden
Negative Ref - Ref
<0.1mm 1.04 0.33-3.29 0.954 - 0.96 0.30-3.11 0.942
0.1-1.0mm 5.94 3.72-9.49 <0.0001* - 4.67 2.81-7.79 <0.0001*
>1.0mm 8.09 5.28-12.4 <0.0001* - 3.89 2.78-8.46 <0.0001*
Dir. LND/ missing 12.1 7.74-19.0 <0.0001* - 4.25 2.08-8.65 <0.0001*
US-FNAC
Both neg. Ref Ref Ref
US susp & FNAC neg 1.45 0.93-2.26 0.100 1.13 0.71-1.78 0.617 1.20 0.76-1.90 0.426
US malig/ FNAC pos 7.56 5.31-10.8 <0.0001* 1.80 1.10-2.96 0.019* 1.52 0.87-2.65 0.144
Gender
Female Ref Ref Ref
Male 1.39 0.99-1.93 0.053 1.48 1.04-2.11 0.029* 1.45 1.02-2.08 0.041*
Age
Cont. 1.01 0.99-1.02 0.136 1.01 1.00-1.02 0.045* 1.01 0.99-1.02 0.064
Location
Extremity Ref Ref Ref
Trunk 0.95 0.67-1.35 0.782 1.12 0.76-1.64 0.567 1.10 0.74-1.62 0.641
Head & neck 1.72 1.08-2.75 0.022* 2.33 1.43-3.79 0.001* 2.27 1.38-3.74 0.001*
Breslow
Cont. 1.11 1.10-1.13 <0.0001* 1.06 1.00-1.08 <0.0001* 1.06 1.03-1.09 <0.0001*
Ulceration
Absent Ref Ref Ref
Present 3.19 2.32-4.39 <0.0001* 1.53 1.07-2.19 0.019* 1.51 1.05-2.17 0.026*
Histology
SSM-LMM Ref Ref
NM/ALM 2.88 2.08-4.00 <0.0001* 1.47 1.01-2.12 0.042* 1.53 1.06-2.22 0.024*
Unknown 1.14 0.54-2.37 0.735 1.07 0.51-2.24 0.859 1.04 0.49-2.17 0.928
Multivariable model 1 was adjusted for: gender, age, primary tumor location, Breslow thickness, ulceration 
status, histologic subtype, SN status (including 43 patients with direct lymph node dissection), and US-
FNAC result. Multivariable model 2 was adjusted for: gender, age, primary tumor location, Breslow thick-
ness, ulceration status, histologic subtype, SN tumor burden and US-FNAC result. A p-value of <0.05 was 
considered statistically signifi cant (marked with an *).Abbreviations: HR, hazard ratio; 95% CI, 95% confi -
dence interval; SN, sentinel node; Ref, reference; Cont., continuous; SSM, superfi cial spreading melanoma; 
LMM, lentigo maligna melanoma; NM, nodular melanoma; ALM, acrolentiginous melanoma; US-FNAC, 
ultrasound-fi ne needle aspiration cytology result; neg., negative; susp, suspicious; malig, malignant; pos, 
positive. ** Positive SN patients include 43 patients undergoing direct lymph node dissection after positive 
US-FNAC.
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Discussion
This study is the largest to date reporting on the value of preoperative assessment of 
the SN with US morphologic criteria in combination with FNAC in melanoma patients. 
We present the long term follow up results of this matured cohort of 1,006 US-FNAC 
examinations in 1,000 patients described previously by Voit et al. 27.
Crude 5-year estimated MSS was significantly worse for patients with suspicious US 
(PP or wandering of the central echo to the rim) and for patients with malignant US (BS 
or LCE) as well as for the combined result of a positive US and/or FNAC (figure 1 and 3). 
The unadjusted HR for a suspicious US in absence of a positive FNAC was slightly higher 
than the reference value of a normal US (and negative FNAC), although not significant. 
The unadjusted HR for a malignant US and or a positive FNAC was significantly higher 
compared to patients with a normal US (table 3). In model 1, adjusted HR for positive 
US-FNAC remained as prognostic indicator with a HR of 1.80 (p=0.019), while in model 
2, where a more detailed classification of SN tumor burden according to the Rotterdam 
criteria was applied, positive US-FNAC was not a significant prognostic indicator, despite 
the still slightly elevated HR of 1.52 (p=0.144). 
Voit et al. found that US-FNAC outcome was clearly correlated with SN tumor burden; 
preoperative US-FNAC correctly identified 61% of SNs with a tumor burden of >1.0mm 
as malignant, and up to 91% of the patients who proceeded directly to LND was correctly 
identified as SN-positive 27. This can explain why a positive US-FNAC result is a relevant 
prognostic indicator for MSS after adjustment for SN status and other prognostic indica-
tors in model 1, and not in model 2 where SN tumor burden already is a covariate. 
Routine US-FNAC in breast cancer patients has shown to upstage a significant amount 
of patients preoperatively, sparing them an unnecessary SNB in up to 18% 15. The fact 
that US-FNAC results remain as prognostic indicator after a median follow-up of 5 years 
in this large cohort emphasizes the potential to incorporate the Berlin US morphology 
criteria combined with FNAC as was done with the Rotterdam criteria in staging of 
melanoma patients in this paradigm shifting era with upcoming systemic therapies for 
melanoma Especially in light of current adjuvant therapy (trials), in a field which lacked 
effective systemic therapy until 2010, the need for early and easy staging is desired by 
patients and physicians. As described previously by Voit et al26, 32, this might be a cost-
effective baseline staging for pT3-4 melanomas and/or primary ulcerated melanomas 33.
Limitations
PP and beginning LCE were no prognostic indicators, nonetheless these are helpful signs 
in selecting which patients should undergo FNAC as well in order to further differentiate 
between a negative or positive US-FNAC result. As was described previously, sensitivity 
of combined US-FNAC was significantly higher than in other studies, possibly due to the 
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fact that the threshold to perform FNAC because of a suspicious US Berlin criterion was 
lower than in other performed studies 27.
The correlation between US-FNAC and SN tumor burden may color survival outcome 
of US-FNAC status, causing signifi cant diff erences in survival which may be more based 
on SN tumor burden than on US-FNAC status. Potentially US-FNAC can best be seen 
as an indicator of high SN tumor burden. Ultimately all patients undergoing US-FNAC 
will undergo a SNB or direct LND in case of positive US-FNAC, thus no potential nodal 
involvement will be missed. Histology of SN or dissected lymph nodes will still be used 
for pathological staging; but patients can skip and be spared a potentially unnecessary 
SNB in case of positive US-FNAC. 
As all US-FNAC negative patients underwent a SNB, no answer can be given on 
whether these patients would have developed nodal basin failure over time if no SNB 
was performed, not taking into account the patients that turned out to be false negative 
after SNB. The 29% false negative rate and regional nodal recurrence rate in US-FNAC 
and SN negative patients is comparable to other reports 7, 34, which is reassuring.
One of the limitations of this study is that all US-FNACs were performed by a select 
group of 3 dedicated ultrasonographists, of whom one performed the fi rst 400 alone. 
The reproducibility of US-FNAC results by another study team has yet to be investigated. 
Eff orts have been made to educate others in recognizing and utilizing the Berlin mor-
phology criteria for targeted US-FNAC of the SN by organizing EORTC Melanoma Group 
sentinel node ultrasound courses since 2012. More recently the GULF trial, a prospective 
multicenter study has started (Dutch trial registry number NTR5193, www.trialregister.
nl). In this feasibility study 120 patients eligible for SNB (melanoma and breast cancer 
patients) will undergo gamma-probe and US guided FNAC of the SN prior to surgical 
removal of the SN, with sensitivity of the gamma-probe guided US-FNAC as main objec-
tive. Additionally, US images of all SNs will be classifi ed according to the Berlin criteria. 
Despite this drawback, US-FNAC of the sentinel node has proven to be accurate and 
sensitive in detecting patients with possible lymph node involvement prior to surgery, 
and has the potential to become a part of standard preoperative diagnostic work up like 
in breast cancer.
Conclusions
The long-term results of this study support the step-wise approach to melanoma pa-
tients. In case of positive FNAC and/or clearly malignant US (BS and/or LCE) they can 
be spared a SNB. In case of PP and negative FNAC, patients could be off ered continue 
US surveillance or SNB for higher risk primary tumors. Completely US-FNAC negative 
patients might only require follow-up and no SN staging, with continue US surveillance 
as addendum for high risk T3/4 and/or ulcerated primaries.
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Abstract
Background Sentinel node (SN) biopsy (SNB) detects clinically occult metastases of 
breast cancer and melanoma in 20-30%. Wound infections, seroma and lymph edema 
occur in up to 10%. Targeted ultrasound (US) of the SN, (with fine needle aspiration cy-
tology (FNAC) if appropriate) has been investigated as a minimally invasive alternative, 
but reported sensitivity rates are too low to replace SNB. Our hypothesis is that the use 
of a handheld gamma probe concomitant with US may improve sensitivity. 
Aim To provide an overview of the current literature on preoperative nodal staging 
of clinical N0 melanoma patients, report on a pilot, and present a study protocol for a 
minimally invasive alternative to the SNB: Gamma probe and Ultrasound guided Fine 
needle aspiration cytology of the sentinel node (GULF trial). 
Methods The GULF trial is a multicenter open single arm observational trial. Newly di-
agnosed cT1b-4N0M0 cutaneous melanoma or cT1-3N0M0 breast cancer patients, aged 
>18 years, presenting for SNB are eligible. 120 patients will be included for preoperative 
targeted gamma probe guided US and FNAC of the SN. Afterwards all patients proceed 
to surgical SNB. Primary endpoint is the sensitivity of FNAC. Secondary endpoints include 
SN identification rate and the histopathological compatibility of Core Needle Biopsy 
and FNAC vs. SNB. Secondary endpoints were investigated in a pilot with 10 FNACs and 
marker placements, and 10 FNACs combined with Core Needle Biopsy. 
Results A pilot in 20 patients showed that SN identification rate was 90%, supporting 
the feasibility of this technique.
Discussion There is broad experience with US (in combination with FNAC) prior to SNB, 
but sensitivity and specificity are too low to completely abandon SNB. Promising alter-
native techniques potentially will replace SNB in the future but more evidence is needed 
in the form of prospective studies. Accurate identification of the SN for US-FNAC has 
been proven feasible in our pilot. When adequate sensitivity can be reached, US-FNAC 
provides a minimally invasive alternative for the surgical SNB procedure.
Trial registration The GULF trial is registered in the Netherlands Trial Registry (NTR), ID: 
NTR5193. May 1st 2015.
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Background
Sentinel node biopsy
With the introduction of sentinel node (SN) biopsy (SNB) as a less invasive alternative 
to elective lymph node dissection for melanoma and breast cancer with clinically nega-
tive lymph nodes, this has become the gold standard for adequate staging. Although 
less invasive than an elective lymph node dissection, SNB is still associated with some 
potential morbidity. Morbidity occurs in up to 10% of patients; wound infections and 
seroma are the most frequently seen complications1, 2. Rarely lymph edema is seen after 
SNB. Around 70-80% of SNB’s are tumor negative after histological assessment, these 
patients cannot benefi t from the SNB procedure. In that light the morbidity of a surgi-
cal SNB procedure is deemed considerable, and any less invasive procedure, if accurate 
enough, would be preferred.
The detection rate of submicrometastases has increased considerably in the past 
decades; adaptation of the melanoma and breast cancer SN sectioning protocols and 
use of standard immunohistochemistry staining enabled pathologists to detect even 
the smallest tumor deposits accurately3-8. This has clear clinical implications; more pa-
tients are diagnosed as SN positive and will be off ered a completion lymphadenectomy 
(CLND)6, 8. It is questionable whether this morbid surgical procedure is justifi ed in cases 
with minimal SN tumor burden9, as several retrospective melanoma studies and recently 
the prospective DeCOG study have shown that survival for this group of melanoma pa-
tients is similar to SN negative patients10-13. In breast cancer, presence of isolated tumor 
cells (≤0.2mm) or micrometastases (>0.2≤2.0mm) is associated with a slightly worse 
prognosis7, 14, but its clinical relevance is debated as well15-17, and CLND is omitted in 
certain groups of patients with a positive SN18. 
Prospective studies currently investigating the therapeutic value of CLND in mela-
noma are the EORTC-1208MG (Minitub)9, including patients with minimal SN tumor 
burden only, and the MSLT2, which included all SN positive patients19. Parallel to this, 
certain adjuvant therapy trials (EORTC 18071, EORTC 1325, Combi-AD) recruit stage IIIA 
patients only in case of ≥1mm SN tumor burden20-22.
 Primary results from the EORTC 18071 show that SN positive patients benefi t the most 
from adjuvant treatment measured as recurrence free survival at 3 years21, 22. In this light, 
it remains worthwhile to keep selecting patients for adjuvant therapy in trial setting 
and/or CLND based on nodal staging, and a cut-off  for detection of (sub)micrometasta-
ses (<1.0mm) may aid in prevention of overtreatment in low risk patients.
Ultrasound guided Fine Needle Aspiration Cytology
Ultrasound (US) guided fi ne needle aspiration cytology (FNAC) or core needle biopsy 
(CNB) may provide a good minimally invasive alternative to SNB. In breast cancer pa-
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tients screening US of the regional lymph node basin is part of the preoperative staging 
process; this way up to 17% of patients undergo axillary lymph node dissection immedi-
ately and are spared a SNB23, 24. Melanoma patients do not routinely undergo a preopera-
tive US of the regional lymph node basin, due to previously reported poor identification 
rates of occult lymph node metastases with US and FNAC25, 26. Several studies have been 
conducted in order to analyze if US (with FNAC or CNB) can replace SNB, but thus far 
reported sensitivity rates for US vary considerably, ranging between 9-94%27, 28. 
For the current study we will focus on melanoma, as the therapeutic value of both SNB 
and CLND are debated, and alternatives for SNB are more limited for this type of cancer. 
In our search for a reliable and accurate minimally invasive alternative to SNB for stag-
ing of clinical N0 melanoma patients, we examined the current available literature and 
performed a systematic search of all major databases to explore whether other methods 
than US guided FNAC may have proven adequate alternatives to SNB.
Literature Overview
All relevant studies on US imaging of regional lymph nodes in melanoma patients 
scheduled for SNB are displayed in Table 1 (search details are given in supplementary 
file 1). Some of the studies mentioned in Table 1 are overlapping; the studies from Voit 
et al29-33 concern the same database with more inclusions over time. In the studies that 
performed US prior to lymphoscintigraphy, sensitivity rates were low, ranging from 4.7% 
to 39%, and specificity rates were high, ranging from 86% to 100%. Two studies did not 
mention the exact timing of US in relation to lymphoscintigraphy; Hocevar et al. reached 
a sensitivity and specificity of 71% and 84%, and Testori et al. reached a sensitivity of 
94% and 90%. 
In the studies that performed a targeted US (i.e. US of the marked “SN” area on the skin 
after lymphoscintigraphy), sensitivity ranged from 22% to 100%, and specificity ranged 
from 62% to 100% (table 1).
Besides US and targeted US with FNAC prior to SNB, several groups have focused 
on development of new imaging techniques for examination of the SN/lymph nodes 
and detection of SN tumor deposits, such as sonoelastography34, 35, contrast enhanced 
US36, and multispectral optoacoustic tomography (MSOT)37 (Table 2). Sonoelastography 
measures tissue consistency; which can be visualized on top of US images using dif-
ferent color shades; red indicating soft tissue, and blue indicating rigid tissue34, 35. As 
metastases tend to be more solid than normal lymph node tissue regions of interest for 
FNAC can be identified. For contrast enhanced US an intravenous contrast agent is ap-
plied to detect possible areas of hyperperfusion or hypoperfusion; indicating potential 
metastatic lesions36. These techniques reached a high sensitivity for identification of SN 
metastases (Table 2).
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Two recently developed techniques for improved SN identifi cation peri-operatively 
are SPECT-US38, 39, and near infrared light fl uorescence imaging40-44. SPECT-US displays 
the location of a radio-active SN in the US images; making it easier for the surgeon to 
locate SN’s in anatomically challenging area’s such as the cervical and occipital area; or 
to guide radiologists for FNAC38, 39. Near infrared light fl uorescence imaging is conducted 
with Indocyanine green as tracer, which can be combined with 99Tc nano-colloids to 
form a hybrid tracer41. Intraoperative identifi cation is similarly accurate to 99Tc-colloid; 
and particularly helpful for SN localization in the cervical and occipital area, where 
overprojection from the 99TC-colloid injection site is a common obstacle. Preoperative 
(transcutaneous) SN identifi cation has reached lower identifi cation rates, due to the 
limited penetration depth of the fl uorescent tracer45.
Summarizing, few US imaging studies have used a method to accurately identify the 
SN prior to US examination and FNAC. This may have contributed to lower than expected 
sensitivity rates for detection of SN metastases in studies where this was not applied. It 
explains why to date no alternative method for SN staging has been adopted in daily 
clinical practice, and the need for such a method remains.
Rationale for a new trial
SN identifi cation
To overcome the problem of suboptimal identifi cation of the SN, we hypothesize that 
use of a handheld gamma probe (Geiger teller) to detect the SN post lymphoscintig-
raphy may further aid the radiologist in accurately identifying the SN for ultrasound 
guided FNAC. Several pilot studies have been performed using this technique in breast 
cancer patients; correct localization of the SN occurred in 75% - 100%46-49. This formed 
the rationale for the GULF Trial (Gamma probe and Ultrasound guided Fine needle 
aspiration cytology of the sentinel node).
Cytology or Histology?
In order to reach the sample size needed for proof of concept with accurate power and 
within an acceptable term, both melanoma patients and breast cancer patients will be 
included in the GULF trial. The SN procedure is uniformly applied for both melanoma 
and breast cancer, and breast cancer patients may equally benefi t from a minimally 
invasive alternative for the SN. All patients will undergo FNAC. Since metastatic size may 
have clinical implications for breast cancer patients18, a subset of 10 breast cancer pa-
tients will undergo CNB additionally after FNAC. This allows for a comparison of results 
between CNB, FNAC and SNB.
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Hypotheses GULF trial
We hypothesize that a sensitivity of 90% with a 95% confidence interval of 80% - 100% 
is achievable. Secondly, we expect that a SN identification rate of more than 75% is 
feasible.
Study aims
· To present a study protocol for a minimally invasive alternative to the sentinel node 
biopsy (GULF trial), with as primary objective to determine whether an acceptable 
sensitivity for US and gamma probe guided FNAC can be achieved.
· Secondary objective is 1) the identification rate of the SN and 2) the histological 
results of CNB versus FNAC and versus SNB.
Prior to starting the GULF-trial, we had to prove the concept of adequate identification of 
the SN. A pilot study focusing on the adequate detection rate of the SN was conducted.
Pilot
After approval of the Ethical Review Board a pilot was performed in 20 patients present-
ing at the Erasmus MC Cancer Institute. All patients underwent gamma probe guided 
US-FNAC after written informed consent. In the 10 first melanoma patients additional 
metallic marker placement (O-Twist-Marker, BIP) was performed after local infiltration of 
the skin and surrounding tissue with 1-10mL lidocaine 2%. Correct identification of the 
SN was assessed by examining the excised SN(s) on presence of the marker. Separately, 
in the first 10 breast cancer patients CNB was performed after FNAC with a 14G needle, 
after local infiltration similar to marker placement. CNB was done for assessment of 
concordance with FNAC results and to detect potential superiority of either technique.
All patients proceeded to OR for SNB, which was performed according to the triple 
technique: preoperative 99Tc lymphoscintigraphy <24h prior to surgery, intradermal 
Table 2. Pilot studies on novel techniques for pre-operative non-invasive detection of melanoma metas-
tases in lymph nodes.
Author, yr Topic No. of 
patients
Technique Sens (%) Spec (%)
Hinz72, 2013 Elastography 36 US + power Doppler: 81 76
Elastography: 91 76
Combined: 95 76
Ogata35, 2014 Elastography 12 US: 77 57
Elastography: 100 71
Stoffels37, 2015 MSOT and indocyanin green 20 MSOT 100 48.6
Overview of pilot studies investigating non-invasive detection of melanoma lymph node metastases. Ab-
breviations: yr, year; Sens, sensitivity; Spec, specificity; US, ultrasound; MSOT, multispectral optoacoustic 
tomography.
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injection of patent blue near the primary tumor site prior to fi rst incision, and peropera-
tive use of a handheld gamma-probe to locate SN(s)50, 51, Lymph nodes were considered 
SN when radioactive and/or blue. A marker was retrieved from the SN in 9 out of 10 pa-
tients; which meant the SN identifi cation rate was 90%. CNB samples were investigated 
on presence of lymphoid tissue. This was present in 6 out of 10 patients. 40% of CNBs 
was not representative. In comparison: FNAC color staining was representative in 19 out 
of 20 patients (95%), and FNAC immunohistochemistry staining was representative in 14 
out of 20 patients (70%).
During the pilot study no safety issues occurred. In the second enrolled study patient 
none of the 2 placed markers were found at histopathological examination of the SN 
and in another patient only 1 of 2 placed markers was found. A detailed shoulder X-ray 
confi rmed the markers were still in situ in both patients. In the latter patient the X-ray 
images were suggestive of marker displacement towards mamma tissue; this was prob-
ably due to intraoperative displacement of the marker during SN removal.
Considering the positive results from this pilot, the study will be continued with an 
expansion of the pilot population in order to reach a suffi  cient sample size according to 
the presented study protocol.
GULF Design
Patients with a newly diagnosed cT1b-4N0M0 cutaneous melanoma or cT1-3N0M0 
breast cancer presenting at the outpatient clinic of the Erasmus MC Cancer Institute, 
and the Netherlands Cancer Institute – Antoni van Leeuwenhoek (only melanomas) will 
be assessed for inclusion. All patients will undergo US and gamma probe guided FNAC 
of the SN. The pilot patients received additional marker placement (n=10) for identifi ca-
tion purposes, or additional CNB (n=10) for assessment of potential benefi t of CNB (i.e. 
histology and size measurement possible) (Figure 1).
Study population
Inclusion criteria
Age ≥ 18 years, new diagnosis of cT1b-4N0M0 cutaneous melanoma or cT1-3N0M0 
breast cancer.
Prior to start of any study related procedure, written informed consent must be given 
according to ICH/GCP and national legislation.
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Figure 1. Study Flowchart GULF Trial
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Exclusion criteria
Clinically suspect lymph node, other known malignancy with potential to disseminate 
to axillary or groin lymph node basins, prior lymph node biopsy, no SN visible at lym-
phoscintigraphy / not identifi able with gamma probe.
Study procedures
US-FNAC
All patients will be admitted to the surgical ward on the day of surgery. First, a lymphos-
cintigram <24 hours prior to SNB will be performed, as is standard procedure. Following 
successful lymphoscintigraphy (i.e. SN(s) is/are visible) the study procedures can start. A 
dedicated radiologist will perform US imaging of the lymph node basin where a SN or 
multiple SNs was/were identifi ed by lymphoscintigraphy. The exact location of the SN(s) 
will be determined using a handheld gamma probe, and by combination with US; the 
assumed SN(s) will be visualized (being a visible lymph node at the center of the hotspot 
found with the gamma probe). FNAC will be performed of all visualized assumed SN(s). 
In case of multiple SNs in one lymph node basin or multiple draining lymph node basins 
with an SN in every basin (for instance a melanoma on the back draining to both axilla 
and groin), FNAC will be performed of all lymph nodes pointed out as primary tier SN by 
the nuclear medicine specialist. For FNAC 1-4 cortical samples will be taken. Whenever 
additional clearly suspect lymph nodes are visible, the radiologist will perform FNAC 
from these nodes as well, as is standard of care. All samples will be transported to the 
pathology lab for analysis. US fi ndings will be recorded according to the Berlin morpho-
logic Criteria to create uniformity in recording per center30. After FNAC, all patients will 
proceed to the operating room for SNB according to standard procedure (as described 
in the Pilot section). Lymph nodes were considered SN when radioactive and/or blue. No 
diagnostic procedure or treatment is postponed or elongated. No additional visits to the 
outpatient clinic are required.
Endpoints:
Primary endpoint: Primary outcome is the sensitivity of gamma probe and US guided 
CNB or FNAC.
Secondary endpoints: Secondary outcome is 1) the identifi cation rate of the SN 2) the 
histological results of CNB versus FNAC and versus SNB.
Ad 1) an identifi cation rate of at least 75% is deemed acceptable (concordant with 
literature). This has been proven feasible in the pilot study.
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Statistical considerations
Sample size and accrual
Based on retrospective data, the prevalence of metastatic SNs is expected to be 30%. 
Our gold standard is the histological outcome of SNB (absence or presence and size 
of metastases in the SN). Submicrometastases (i.e. <0.1 mm at any site or 0.4mm sub-
capsular) in melanoma patients, and isolated tumor cells (i.e. ≤0.2mm) in breast cancer 
patients will be considered negative: a negative FNAC is accepted in these cases. Based 
on previous reports, we expect to find around 10% of these submicrometastases and 
isolated tumor cells in both melanoma and breast cancer patients 52, 53. Considering this, 
the maximum achievable sensitivity of FNAC will be 90%. For this sensitivity, and a 95% 
confidence interval of 80-100% (With a two-sided significance level α = 0.05 and power 
1 – β = 0.8), the required sample size is 116 considering a 30% prevalence of metastatic 
SNs. Around 3% of patients are expected to have a negative lymphoscintigram: the 
sample size will be increased to 120 patients. With an average accrual rate of 60 patients 
per year, maximum accrual will be met at 2 years post start of study.
Statistical analysis plan
The main analysis addressing the primary endpoint will be performed after inclusion of 
all 120 patients. No interim analysis is planned for this endpoint.
Ethical considerations
This study has been approved by the Erasmus MC medical-ethical committee. The study 
will be conducted according to the principles of the Declaration of Helsinki and in ac-
cordance with national and regional legislation, guidelines, regulations and acts.
Discussion
Currently SNB is the most important staging procedure for clinically N0 melanoma 
patients, especially in the light of trial participation for adjuvant therapies based on 
N-status 20, 21, 54. The therapeutic role of SNB for melanoma is still under debate 55-57. Con-
sidering the fact that this is a surgical staging procedure associated with complications 
in up to 10% of patients, our group sought to investigate a more minimally invasive 
alternative.
The ongoing improvement of imaging techniques (i.e. more accurate and detailed 
US imaging) and increased experience with FNAC renders combined US-FNAC as a high 
potential minimally invasive alternative for surgical SNB 31, 32. Correct transcutaneous 
identification of the SN forms the main obstacle for broad application of this technique 
as this is key in obtaining reliable FNAC.
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The current study aims to give an overview of the current melanoma literature, report 
a pilot and present a study protocol for a minimally invasive technique to investigate the 
SN using gamma probe guided US-FNAC.
Overview of the Literature
The studies presented provide evidence that it is diffi  cult to detect clinically occult lymph 
node metastases in melanoma patients, and although some studies have achieved 
high sensitivity and specifi city rates, these results have not been reproduced by other 
groups. There are many diff erences between the reported studies; namely retrospec-
tive vs. prospective study setting; US prior to lymphoscintigraphy vs. targeted US after 
lymphoscintigraphy; the number of persons performing US and their expertise; varia-
tion in US morphology criteria used to discriminate between benign and suspicious or 
malignant lymph nodes; and use of FNAC or not. Al these factors will have contributed 
to the outcome of these studies. It is interesting to see that sensitivity rates are low in 
the studies that performed an US of the entire lymph node basin without knowing the 
location of the SN(s), but that even in the studies were targeted US of the SN area was 
applied, sensitivity rates could be as low as 22%58 and as high as 82%31 or even a perfect 
100%36 as well. Thompson et al. proposed a possible explanation for these disparate 
results; many of the micrometastases present in SNs are too small to be detected by 
the US-equipment used59, 60. However, Voit et al. demonstrated that it was possible to 
successfully perform a FNAC in a lesion as small as 0.4 mm. Nevertheless, most smaller 
SN metastases will be overlooked by US and/or missed by FNAC. The question is if this 
has any clinical implications.
As long as US-imaging is limited by a detection limit, and alternative imaging tech-
niques are tested in pilot settings, the need for a reliable, minimal invasive easy to 
perform and replicate method to assess SN status remains. Hence the presentation of 
the GULF trial study protocol here.
Pilot
Our pilot results show that correct identifi cation of the SN for FNAC was possible in 90%, 
and that the sampled material was representative in 95% of FNAC samples. CNB was 
representative in only 60%. This confi rms that the described technique for targeted US-
FNAC of the SN is feasible. CNB will not be added to the study procedure considering the 
low rate of representative tissue in the pilot phase.
If an acceptable sensitivity can be achieved for FNAC, patients can proceed to un-
dergo radical lymph node dissection immediately in case of positive FNAC, bypassing 
the SNB procedure. When the FNAC sample is negative, surgeons can choose to perform 
a SNB or continue with only surgical excision of the primary tumor and monitoring of 
potential lymph node involvement at follow up visits. This way up to 80% of patients 
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eligible for SNB can be spared this invasive procedure and the risk of morbidity related 
to this procedure. Furthermore, for melanoma patients this would mean that general 
anesthesia is no longer needed, as WLE can be performed under local anesthesia. Ulti-
mately operative nodal staging may become completely obsolete.
Conclusions
The literature on pre-operative assessment of regional lymph nodes with US in clinically 
N0 melanoma patients is disparate. Targeted US of the SN area in combination with 
FNAC or other new techniques has potential to become a minimally invasive alternative 
for the SNB, however, findings need to be replicated in prospective clinical trials first. A 
pilot with gamma probe guided US-FNAC show that accurate SN identification in up to 
90% of patients is feasible. Our group presents a study protocol of the Gamma probe and 
ULtrasound guided Fine needle aspiration cytology of the sentinel node Trial (GULF trial) as 
a potential improvement to the reported US-FNAC techniques and ultimately even a 
possible replacement of the SNB. 
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Supplementary fi le 1. Literature Search 22 April 2016
Subject: Melanoma echography lymph nodes 
Database Number of studies Number of unique 
studies
Embase.com 347 340
Medline Ovid 213 28
Web of science 286 122
Cochrane 5 0
PubMed publisher 5 4
Google scholar 100 69
Total 956 563
Embase.com n=347
(‘melanoma’/exp OR (melanom*):ab,ti) AND (‘lymph node’/exp OR ‘lymph node biopsy’/
exp OR ‘lymph node metastasis’/exp OR (lymph-node* OR sentinel-node* OR SLNB OR 
SLN OR SLNs OR SN):ab,ti) AND (‘echography’/exp OR ultrasound/de OR (echogra* OR 
ultraso* OR (us NEXT/1 (guid* OR examin* OR imag*)) OR preoperative-US OR sonogra* 
OR optoacoust*):ab,ti) AND (‘diagnostic accuracy’/exp OR ‘diagnostic test accuracy 
study’/de OR ‘diagnostic error’/exp OR ‘predictive value’/de OR ‘diagnostic value’/de 
OR ‘sensitivity and specifi city’/exp OR ‘early diagnosis’/de OR ‘reproducibility’/de OR 
‘observer variation’/de OR (((diagnos* OR ultrasound OR us) NEAR/6 (accurac* OR error* 
OR metast* OR abilit* OR value OR improv* OR mis OR missed)) OR ((Micrometasta* OR 
metasta* OR sentin* OR sn OR sln) NEAR/6 (identif* OR detect*)) OR (false NEXT/1 (posi-
tive* OR negative*)) OR predictive-value* OR npv OR ppv OR sensitiv* OR specifi c* OR 
(early NEAR/3 (diagnos* OR detect*)) OR reproducib* OR Misdiagnos* OR ((observer* 
OR interobserver* OR intraobserver*) NEAR/3 (varia* OR bias))):ab,ti) NOT ([Conference 
Abstract]/lim OR [Letter]/lim OR [Note]/lim OR [Editorial]/lim)
Medline Ovid  n=213
(“melanoma”/ OR (melanom*).ab,ti.) AND (“Lymph Nodes”/ OR “Sentinel Lymph Node 
Biopsy”/ OR (lymph-node* OR sentinel-node* OR SLNB OR SLN OR SLNs OR SN).ab,ti.) 
AND (exp “Ultrasonography”/ OR “Ultrasonography”.xs. OR Ultrasonics/ OR (echogra* OR 
ultraso* OR (us ADJ (guid* OR examin* OR imag*)) OR preoperative-US OR sonogra* OR 
optoacoust*).ab,ti.) AND (exp “Diagnostic Errors”/ OR “diagnostic value”/ OR exp “sensi-
tivity and specifi city”/ OR exp “early diagnosis”/ OR “Reproducibility of Results”/ OR (((di-
agnos* OR ultrasound OR us) ADJ6 (accurac* OR error* OR metast* OR abilit* OR value 
OR improv*)) OR ((Micrometasta* OR metasta* OR sentin* OR sn OR sln) ADJ6 (identif* 
OR detect*)) OR (false ADJ (positive* OR negative*)) OR predictive-value* OR npv OR ppv 
OR sensitiv* OR specifi c* OR (early ADJ3 (diagnos* OR detect*)) OR reproducib* OR Mis-
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diagnos* OR ((observer* OR interobserver* OR intraobserver*) ADJ3 (varia* OR bias))).
ab,ti.) NOT (letter OR news OR comment OR editorial OR congresses OR abstracts).pt.
Cochrane  n=5
((melanom*):ab,ti) AND ((lymph-node* OR sentinel-node* OR SLNB OR SLN OR SLNs OR 
SN):ab,ti) AND ((echogra* OR ultraso* OR (us NEXT/1 (guid* OR examin* OR imag*)) OR 
preoperative-US OR sonogra* OR optoacoust*):ab,ti) AND ((((diagnos* OR ultrasound OR 
us) NEAR/6 (accurac* OR error* OR metast* OR abilit* OR value OR improv* OR mis OR 
missed)) OR ((Micrometasta* OR metasta* OR sentin* OR sn OR sln) NEAR/6 (identif* OR 
detect*)) OR (false NEXT/1 (positive* OR negative*)) OR predictive-value* OR npv OR 
ppv OR sensitiv* OR specific* OR (early NEAR/3 (diagnos* OR detect*)) OR reproducib* 
OR Misdiagnos* OR ((observer* OR interobserver* OR intraobserver*) NEAR/3 (varia* OR 
bias))):ab,ti) 
Web of science  n=286
TS=(((melanom*)) AND ((lymph-node* OR sentinel-node* OR SLNB OR SLN OR SLNs 
OR SN)) AND ((echogra* OR ultraso* OR (us NEAR/1 (guid* OR examin* OR imag*)) OR 
preoperative-US OR sonogra* OR optoacoust*)) AND ((((diagnos* OR ultrasound OR 
us) NEAR/5 (accurac* OR error* OR metast* OR abilit* OR value OR improv* OR mis OR 
missed)) OR ((Micrometasta* OR metasta* OR sentin* OR sn OR sln) NEAR/5 (identif* OR 
detect*)) OR (false NEAR/1 (positive* OR negative*)) OR predictive-value* OR npv OR 
ppv OR sensitiv* OR specific* OR (early NEAR/2 (diagnos* OR detect*)) OR reproducib* 
OR Misdiagnos* OR ((observer* OR interobserver* OR intraobserver*) NEAR/2 (varia* OR 
bias)))) )
PubMed publisher  n=5
(“melanoma”[mh] OR (melanom*[tiab])) AND (“Lymph Nodes”[mh] OR “Sentinel Lymph 
Node Biopsy”[mh] OR (lymph-node*[tiab] OR sentinel-node*[tiab] OR SLNB OR SLN OR 
SLNs OR SN)) AND (“Ultrasonography”[mh] OR “Ultrasonography”[sh] OR Ultrasonics[mh] 
OR (echogra*[tiab] OR ultraso*[tiab] OR us guid*[tiab] OR us examin*[tiab] OR us 
imag*[tiab] OR preoperative-US[tiab] OR sonogra*[tiab] OR optoacoust*[tiab])) AND (“Di-
agnostic Errors”[mh] OR “diagnostic value”[mh] OR “sensitivity and specificity”[mh] OR 
“early diagnosis”[mh] OR “Reproducibility of Results”[mh] OR (diagnostic accurac*[tiab] 
OR diagnostic error*[tiab] OR diagnostic abilit*[tiab] OR diagnostic value*[tiab] OR 
false positive*[tiab] OR false negative*[tiab] OR predictive-value*[tiab] OR npv OR 
ppv OR sensitiv*[tiab] OR specific*[tiab] OR early diagnos*[tiab] OR early detect*[tiab] 
OR reproducib*[tiab] OR Misdiagnos*[tiab] OR observer varia*[tiab] OR interobserver 
varia*[tiab] OR intraobserver varia*[tiab] OR observer bias*[tiab] OR interobserver 
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bias*[tiab] OR intraobserver bias*[tiab])) NOT (letter[pt] OR news[pt] OR comment[pt] 
OR editorial[pt] OR congresses[pt] OR abstracts[pt]) AND publisher[sb]
Google scholar n=100
melanoma “lymph|sentinel node|nodes” echography|ultrasound|ultrasonographic|ult
rasonography “diagnostic|predictive accuracy|errors|ability|value”|misdiagnosis|”false 
positives|negatives” 
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Abstract
Background Worldwide, sentinel node biopsy (SNB) is the recommended staging pro-
cedure for stage I/II melanoma. Most melanoma guidelines recommend re-excision plus 
SNB as soon as possible after primary excision. To date, there is no evidence to support 
this timeframe. Aim: To determine melanoma specific survival (MSS) for time intervals 
between excisional biopsy and SNB in SNB positive patients.
Methods Between 1993-2008, 1 080 patients were diagnosed with a positive SNB in 
nine Melanoma Group centers. We selected 1 015 patients (94%) with known excisional 
biopsy date. Time interval was calculated from primary excision until SNB. Kaplan-Meier 
estimated MSS was calculated for different cutoff values. Multivariable analysis was 
performed to correct for known prognostic factors.
Results Median age was 51 years (Inter Quartile Range (IQR) 40-62 years), 535 (53%) 
were men, 603 (59%) primary tumors were located on extremities. Median Breslow 
thickness was 3.00mm (IQR 1.90-4.80mm), 442 (44%) were ulcerated. Median follow-up 
was 36 months (IQR 20-62 months). Median time interval was 47 days (IQR 32-63 days). 
Median Breslow thickness was equal for both <47 days and ≥47 days interval: 3.00mm 
(1.90-5.00mm) vs 3.00mm (1.90-4.43mm) (p=0.402). Sentinel node tumor burden was 
significantly higher in patients operated ≥47 days (p=0.005). Univariate survival was not 
significantly different for median time interval. Multivariable analysis confirmed that 
time interval was no independent prognostic factor for MSS. 
Conclusions Time interval from primary melanoma excision until SNB was no prognos-
tic factor for MSS in this SNB positive cohort. This information can be used to counsel 
patients. 
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Introduction
Parallel to the increasing incidence of primary cutaneous melanomas, sentinel node 
biopsies (SNB) are being performed more often. This is the current standard to detect 
early lymph node micrometastases1-3. 
As recommended by the American Joint Committee on Cancer (AJCC), as well as the 
American Society of Clinical Oncology (ASCO) and the Society of Surgical Oncology 
(SSO), by performing a SNB, it is possible to provide accurate staging of intermediate 
thickness (Breslow 1.0 – 4.0mm) primary cutaneous melanoma4, 5. This way, patients 
can be provided more information about their prognosis 4, 6, 7. Sentinel node (SN) 
status can help to select patients who might benefit from completion lymph node 
dissection (CLND) and / or adjuvant systemic therapies in trial setting, for instance the 
EORTC 18991 study on pegylated interferon alfa and the EORTC 18071 study on ipilim-
umab8, 9. Currently no uniform recommendation exists on the maximum allowed time 
interval between primary melanoma excision and wide local excision (WLE) combined 
with SNB. Most national melanoma guidelines advise to perform WLE and SNB as soon 
as possible within an acceptable time frame. The Dutch national melanoma guideline 
advocates a strict maximum time interval of six weeks10. This suggests a detrimental 
effect on survival if not adhered to. To date, only two studies have reported on this 
topic. Parrett et al. found no adverse effects on survival for a time interval of <40 days 
vs. > 40 days, while Tejera-Vaquerizo et al. reported a detrimental effect of a time 
interval of <40 days at the expense of SN negative patients11, 12. These contradicting 
findings are not sufficient to answer the question which effects, if any, time interval 
may have on survival. 
One of the negative aspects of advising a short time frame for SNB is the incentive 
for general practitioners (GP’s) and dermatologists to perform high urgency referrals. 
The potentially increased patient anxiety due to longer wait times (depending on the 
country’s healthcare system) may also play a considerable role in this. Altogether this 
poses the need to objectively describe the possible infl uences of the time interval be-
tween primary diagnosis and WLE plus SNB on survival. We hypothesize that this time 
interval may be associated with a diff erence in survival. Aim of the study is to investigate 
if time interval between primary diagnosis and WLE plus SNB is associated with survival 
diff erences in a SN positive melanoma population. 
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Methods
Patients
For purposes of this current study, a retrospective cohort of SN positive patients, 
previously collected and described, was used13. In brief, this cohort contained 1 080 
SN positive patients from nine European Organization for Research and Treatment of 
Cancer (EORTC) Melanoma Group centers, undergoing SNB between 1993 and 2008. The 
study was performed in accordance with local ethics committee guidelines. In total, 1 
015 patients (94%) were selected with known date of primary melanoma excision. Col-
lected data included: gender, age, date of primary excision, date of SNB, primary tumor 
characteristics i.e. location, Breslow thickness, ulceration, CLND data i.e. performed yes/
no, positive non-SNs yes/no, and follow-up (FU).
Melanoma Diagnosis
Diagnosis of the primary melanoma was based on histopathologic examination of an ex-
cisional biopsy in all cases. Excisional biopsy was performed with total thickness excision 
and a narrow margin, as described in the American Association of Dermatology Guide-
lines and the National Cancer Comprehensive Network Clinical Practice Guidelines14, 15. 
Date of diagnosis was defined as the date of excisional biopsy. All patients treated at the 
participating centers were worked up for SNB in line with the recommendations stated 
by the European Society of Medical Oncology 16. 
Surgical Procedure and Pathology: 
SNB was performed if Breslow thickness was > 1.0 mm or if risk factors were present such 
as ulceration or high Clark level (IV or V), regression, or high mitotic rate (>1 count/field). 
Generally, WLE (with a margin of 1-2 cm depending on the Breslow thickness) and SNB 
were performed in the same setting. In all centers the triple technique was used for SNB; 
consisting of pre-operative lymphoscintigraphy within 24 hours prior to the procedure; 
perioperative injection of patent blue near the primary tumor site and use of an intra-
operative handheld gamma detection probe to locate the SN(s) 17, 18. A lymph node was 
defined as SN, if it was blue and / or hot (in situ: intraoperative gamma detector count 
of at least 3x background count, ex situ: intraoperative gamma detector count of at least 
10x background count)13. Pathology review and reports were conducted according to 
the EORTC Melanoma Group Pathology Protocol, including scoring of SN tumor burden 
according to the Rotterdam criteria19-21.
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Outcome measures: 
Time interval until SNB was the variable of interest (dependent variable) in this study. 
The primary endpoint was melanoma specifi c survival (MSS). Secondary endpoints were 
disease free survival (DFS); overall survival (OS); and SN tumor burden. 
Statistics
Time until SNB was calculated from date of diagnosis until SNB date. FU was calculated 
from SNB date to last FU date or death. DFS was calculated from SNB date until date of 
fi rst recurrence (any site). OS was calculated from SNB date until death (any cause) or last 
FU. MSS was calculated from SNB date until death by melanoma or last FU, deaths by 
other causes were censored (considered as withdrawal from population).
Patients were divided into two categories based on time interval: early SNB (< median) 
vs, late SNB (≥ median). Additionally, the fi rst (Q1) and third quartile (Q3) of time interval 
were tested as binominal categories, and fi rst (Q1) and last quartile (Q4) were tested 
against each other to detect diff erences between both outer quartiles. Breslow thickness, 
ulceration, SN tumor burden, gender and location of the primary tumor were analyzed 
per time interval category in order to investigate the possibility of diff erences in distri-
bution indicating a selection bias in favor of early or late SNB. Kaplan-Meier estimated 
MSS was calculated per time interval category. Cox proportional hazard multivariable 
analysis was performed adjusting for age, gender, Breslow thickness, histology type, 
ulceration, Clark level, SN tumor burden, CLND category (performed/not performed), 
additional positive non-SNs and time interval as continuous variable. The maximum 
allowed degrees of freedom in the model were based on the number of events, not 
exceeding one tenth of the number of events. 
A p-value of <0.05 was considered statistically signifi cant. All statistical analyses were 
performed using SPSS Version 21.0 (IBM Corp. Released 2012. IBM SPSS Statistics for 
Windows, Version 21.0. Armonk, NY: IBM Corp.). 
Results
In total 1 015 patients (93.9%) were selected of whom diagnosis date was known and 
time interval was less than 154 days (22 weeks). Median age at diagnosis was 51 years 
(IQR 40-62 years). Median FU was 36 months (IQR 20 -62 months), median DFS was 27 
months (11 – 57 months). Table 1 summarizes the baseline characteristics of the study 
population per time interval category. 
Regression and mitotic rate were only recorded in a minority of patients, hence 
these variables were not included for further analysis. Median Breslow thickness was 
3.00 mm (IQR 1.90 – 4.80mm). Median time interval per center is shown in table 2. 
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Table 1. Baseline Characteristics of Sentinel Node Positive Patients (N = 1 015)
Characteristic < 47 days ≥ 47 days All p
N (%) 507 (50) 508 (50) 1 015 (100)
Center 
1 53 (10.5) 62 (12.2) 115 (11.3)
2 82 (16.2) 4 (0.8) 86 (8.5)
3 101 (19.9) 120 (23.6) 221 (21.8)
4 102 (20.1) 102 (20.1) 204 (20.1)
5 22 (4.3) 70 (13.8) 92 (9.1)
6 25 (4.9) 41 (8.1) 66 (6.5)
7 60 (11.8) 46 (9.1) 106 (10.4)
8 20 (3.9) 36 (7.1) 56 (5.5)
9 42 (8.3) 27 (5.3) 69 (6.8) 0.005*
Gender
Female 228 (45.0) 252 (49.6) 480 (47.3)
Male 279 (55.0) 256 (50.4) 535 (52.7) 0.139
Age, years
≤ 51 255 (50.3) 264 (52.0) 520 (51.1)
> 51 252 (49.7) 244 (48.0) 496 (48.9) 0.594
Location
Extremity 314 (61.9) 289 (56.9) 603 (59.4)
Trunk 177 (34.9) 204 (40.2) 381(37.5)
Head/neck 16 (3.2) 15 (3.0) 31 (3.1) 0.122
Histology
SSM 179 (35.3) 197 (38.8) 376 (37.0)
NM 172 (33.9) 157 (30.9) 329 (32.4)
Other 25 (4.9) 15 (3.0) 40 (4.0)
Unknown 131 (25.8) 139 (27.4) 270 (26.6) 0.538
Breslow Thickness, mm
T1 (</= 1.00) 29 (5.7) 20 (3.9) 49 (4.8)
T2 (1.01-2.00) 118 (23.3) 139 (27.4) 257 (25.3)
T3 (2.01-4.00) 201 (39.6) 210 (41.3) 411 (40.5)
T4 (>4.00) 159 (31.4) 137 (27.0) 296 (29.2)
Missing - 2 (0.4) 2 (0.2) 0.236
Clark level
II 12 (2.4) 20 (3.9) 32 (3.2)
III 120 (23.7) 133 (26.2) 253 (24.9)
IV 309 (60.9) 276 (54.3) 585 (57.6)
V 48 (9.5) 52 (10.2) 100 (9.9)
Unknown 18 (3.6) 27 (5.3) 45 (4.4) 0.567
Ulceration
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The proportion of patients undergoing SNB early (<47 days) diff ered signifi cantly per 
center, due to more early surgical procedures in Center 2 and Center 9 (operated within 
47 days: 95.3% and 60.9% vs. 23.9% - 56.6% in the remaining centers) (table 1, table 2). 
Median FU did not diff er between patients operated at <47 days (37 months, IQR 19 – 62 
months) vs. patients operated at ≥47 days (35 months, IQR 21 – 62 months) (p=0.632). 
Table 1. Baseline Characteristics of Sentinel Node Positive Patients (N = 1 015) (continued)
Characteristic < 47 days ≥ 47 days All p
Absent 249 (49.1) 262 (51.6) 511 (50.3)
Present 229 (45.2) 213 (41.9) 442 (43.5)
Unknown 29 (5.7) 33 (6.5) 62 (6.1) 0.550
SN tumor burden
<0.1mm 60 (11.8) 52 (10.2) 112 (11.0)
0.1 – 1.0mm 238 (46.9) 199 (39.2) 437 (43.1)
>1.0mm 209 (41.2) 257 (50.6) 466 (45.9) 0.005*
CLND performed
No 24 (4.7) 22 (4.3) 46 (4.5)
Yes 468 (92.3) 482 (94.9) 950 (93.6)
Unknown 15 (3.0) 4 (0.8) 19 (1.9) 0.276
Positive non SNs
No 380 (75.0) 415 (81.7) 795 (78.3)
Yes 110 (21.7) 87 (17.1) 197 (19.4)
Unknown 17 (3.4) 6 (1.2) 23 (2.3) 0.009*
Time interval, median (IQR) 32 (26 – 40) 63 (54 – 75) 47 (32 – 63) 0.331
N, number of patients; IQR, inter quartile range; SSM, superfi cial spreading melanoma; NM, nodular mela-
noma; LMM, lentigo maligna melanoma; ALM, acrolentiginous melanoma; CLND, completion lymph node 
dissection; SN, sentinel node. * signifi cance reached at p<0.05.
Table 2. Time Interval Between Melanoma Diagnosis and Sentinel Node Biopsy per Center
Center Time interval in days: median, (inter quartile range)
1 48 (36 – 61)
2 9 (0 - 30)
3 49 (36 – 63)
4 47 (33 – 61)
5 63 (48 – 73)
6 53 (37 – 69)
7 41 (29 – 62)
8 50 (41 – 64)
9 37 (21 – 59)
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Figure 1. 5 Year Estimated Melanoma Specific Survival (MSS) for Median Sentinel Node Biopsy (SNB) Time 
Interval. <47 days (blue line) and ≥47 days (red line). 
Figure 2. 5 Year Estimated Melanoma Specific Survival (MSS) for Sentinel Node Biopsy (SNB) Time Interval 
Outer Quartiles. First quartile Q1, <32 days (blue line) and fourth quartile Q4, >63 days (red line). 
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Table 3. Univariable and Multivariable Analysis on 5 Year Melanoma Specifi c Survival (MSS) (N = 1 015)
Covariate Univariable Multivariable
HR 95% CI P HR 95% CI P
Age, continuous 1.01 1.00 – 1.02 0.043* 1.01 0.99 – 1.01  0.322
Gender
Female 1 1
Male 1.31 1.00 - 1.72 0.046* 1.37 1.04 – 1.81 0.024*
Histology            
SSM 1      1    
NM 1.40 1.01 - 1.93 0.042* 0.96 0.68 – 1.35  0.959
Other 2.04 1.10 - 3.76 0.023*  1.75  0.92 – 3.34 0.088
Unknown 1.39 0.98 - 1.99 0.065  1.32  0.89 – 1.95 0.170
Clark level
II 1 1
III 1.34 0.48 - 3.75 0.576 1.61 0.57 - 4.57 0.372
IV 1.98 0.73 - 5.36 0.178 2.09 0.77 - 5.73 0.150
V 3.84 1.37 - 10.8 0.011* 2.42 0.84 - 6.96 0.101
Unknown 2.70 0.86 - 8.47 0.090 2.21 0.67 - 7.28 0.194
Ulceration            
Absent 1     1    
Present 2.19 1.65 - 2.91 <0.0001* 1.67 1.24 - 2.26 0.001*
Unknown 1.73 0.98 - 3.05 0.059 1.44 0.77 – 2.70 0.254
Breslow, continuous 1.07 1.06 – 1.09 <0.0001* 1.05 1.02 – 1.07 0.0002*
Tumor burden            
< 0.1 mm 1     1    
0.1 – 1.0 mm 3.20 1.48 - 6.93 0.003* 2.85 1.31 - 6.21 0.008*
> 1.0 mm 5.96 2.79 - 12.7 <0.0001* 4.14 1.91 – 9.00 0.0003*
CLND done
No 1 1
Yes 1.12 0.53 – 2.37 0.775 0.63 0.29 – 1.37 0.244
Unknown 1.99 0.58 – 6.81 0.271 0.61 0.06 – 6.29 0.674
Positive non-SNs
No 1 1
Yes 2.47 1.86 – 3.28 <0.0001* 2.27 1.68 – 3.05 <0.0001*
Unknown 2.37 0.97 – 5.79 0.058 2.51 0.34 – 18.4 0.366
Time interval, continuous 1.00 0.99 – 1.01 0.721 1.00 0.99 – 1.01 0.567
Unknown 1.73 0.98 - 3.05 0.059 1.44 0.77 – 2.70 0.254
Abbreviations: MSS, melanoma specifi c survival; N, number of patients; HR, Hazard Ratio; 95% CI, 95% Con-
fi dence Interval; *, signifi cant at p<0.05; SSM, superfi cial spreading melanoma; NM, nodular melanoma; n.s., 
not signifi cant; CLND, completion lymph node dissection; SN, sentinel node.
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5-year Estimated Kaplan-Meier MSS showed no significant difference in survival for 
early SNB (<47 days) vs. late SNB (≥ 47 days) (Figure 1). For time interval categories Q1 
and Q3 respectively, also no significant difference in MSS or DFS was seen (data not 
shown). Survival was not different between both outer quartiles; 5-yr MSS for Q1 (<32 
days) was 70% vs. 72% for Q4 (>63 days), p=0.574 (Figure 2).
Univariable logistic Cox regression analyses showed a significant difference in 5-year 
estimated MSS for the following variables: older age (as continuous variable), gender, 
histological subtype, Clark level, ulceration, Breslow thickness, SN tumor burden, and 
positive non-SNs at CLND (table 3). Non-significant on univariable analyses were: pri-
mary tumor location, center, CLND category and time interval (as continuous variable). 
A Cox proportional hazard multivariable analysis was performed with inclusion of the 
significant factors on univariable analyses as mentioned above, CLND category and time 
interval to adjust for any possible occult selection bias on univariable analysis. Only male 
gender, presence of ulceration, higher Breslow thickness, SN tumor burden >0.1mm and 
positive non-SNs at CLND remained as independent prognostic factors for 5 year MSS 
(table 3).
Time interval from primary excision to SNB was no independent prognostic factor for 
5 year MSS after adjustment for potential confounding factors on multivariable analysis. 
DFS and OS were calculated for the entire cohort and each co-variable per time interval 
category (results not shown). Results were similar to the MSS data, namely that time 
interval was not a prognostic factor. 
For DFS, the following additional prognostic indicators were found: increasing age (HR 
1.01, 95% CI 1.00 – 1.01, p=0.050), center 2 (HR 0.59, 95% CI 0.35 – 0.98, p=0.040), center 
4 (HR 0.51, 95% CI 0.31 – 0.83, p=0.006), center 5 (HR 0.47, 95% CI 0.29– 0.77, p=0.002), 8 
(HR 0.33, 95% CI 0.17 – 0.62, p=0.001) and 9 (HR 0.24, 95% CI 0.12 – 0.48, p=0.001), and 
Clark level IV (HR 2.07, 95% CI 1.01 – 4.24, p=0.048) and V (HR 2.21, 95% CI 1.03 – 4.76, 
p=0.042). 
Discussion
The MSLT 1 final report showed no difference in 10-year MSS for WLE and SNB followed 
by immediate CLND versus WLE alone and nodal observation followed by delayed 
therapeutic lymph node dissection if necessary22. Sub analyses in node positive patients 
with intermediate-thickness melanoma (1.2-3.5mm) showed a significantly improved 
10-year distant DFS and MSS in favor of SNB. Considering this, any potential impact of 
the time interval until SNB on survival might more likely become detectable in patients 
with nodal disease, i.e. a positive SN. This formed the rationale to perform the current 
study with SN positive patients. 
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In this study, 5-year estimated MSS is not signifi cantly diff erent for short versus lon-
ger time intervals (Figure 1, fi gure 2). SN tumor burden according to the Rotterdam 
criteria13, 20 is signifi cantly more often high in those patients undergoing SNB after a 
time interval of 47 days or more. Thus it may seem that late performance of SNB might 
have an adverse eff ect on tumor burden. Oppositely of the increase of SN tumor bur-
den with a longer time interval, the risk of additional positive non-SNs at CLND was 
higher in patients with early SNB (≤47 days). In multivariable logistic regression (data 
not shown), time interval was not correlated to CLND outcome, but Center was. This 
has been addressed by van der Ploeg et al23. Since time intervals are diff erent between 
centers (table 2), there is a strong correlation between center and time interval. This 
could explain why it would seem that time interval has infl uence on the proportion of 
patients with positive non-SNs at CLND while in truth proportion of positive non-SNs is 
associated with the center of treatment. 
After correcting for tumor burden, CLND outcome, and other known prognostic 
factors in a multivariable model time interval cannot be identifi ed as a detrimental 
prognostic factor for MSS. This is in line with the study of Parrett et al. which concerned 
491 SN positive and negative patients from a single institution12. With a median time 
interval of 40 days, no diff erences in DFS, OS and MSS were found, nor any signifi cant 
diff erence in SN positivity rates. 
Importantly, the current study consists of SN positive patients only. Since SN positive 
patients have a worse prognosis, the outcome of this study strengthens the fi ndings of 
Parrett et al. SN negative patients have not been investigated in the current study, but 
eff ect of time interval on survival is not expected in these low-risk patients. Interestingly, 
Tejera-Vaquerizo et al. did fi nd a detrimental eff ect of a short time interval on survival for 
SN negative patients11. They hypothesized that a shorter time interval and worse prog-
nosis were associated due to surgeons prioritizing patients for surgery when primary 
tumor features were worrisome. Validation of these data is needed, as the described 
fi ndings are counterintuitive. 
The phenomenon that high SN tumor burden was more frequently observed in those 
patients undergoing SNB at a later time interval might cause one to consider a correla-
tion between SN tumor burden and time interval. 
When stratifying for SN tumor burden in Kaplan-Meier estimated survival analyses, no 
signifi cant diff erences in MSS are seen for time interval (data not shown). After stratifi ca-
tion for time interval <47 days vs. >47 days, SN tumor burden did distinguish clearly 
between good, intermediate and poor prognosis (Figure S1). The fact that there was 
no unadjusted survival diff erence between the group with a time interval of <47 days 
versus the group with a time interval of ≥ 47 days while the proportion of patients with 
a high SN tumor burden was slightly larger in the latter may be explained by the fact that 
survival is infl uenced by many variables and that the net eff ect canceled out the slightly 
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more frequent high SN tumor burden in the latter group. The fact that survival for high 
SN tumor burden found with early SNB versus high SN tumor burden found with late 
SNB is not different confirms that SN tumor burden is a prognostic factor regardless of 
SNB timing. 
It is remarkable that there are differences in DFS across centers and not in MSS. Due to 
the retrospective nature of this study, the exact timing of follow-up visits is not known 
for all centers. It could be that more frequent follow-up visits in these centers led to 
a lead-time bias effect. Another possibility could be that these centers treated more 
patients with low risk primaries. This was not the case, since centers with a low median 
Breslow thickness had more ulcerated tumors and vice versa. As detailed follow-up 
information including date and site of first recurrence was not known for all patients, 
the lower HR for DFS in five out of nine participating centers may also be explained by a 
selection bias due to missing data. 
There is sparse literature with regard to the maximum allowable time interval for 
SNB. Two large prospective trials have included a maximum time interval as inclusion 
criterion. These are the MSLT I trial, with a maximum allowed time interval to SNB of 12 
weeks 24, and the SUNBELT trial, where the maximum allowed time interval was 90 days 
(=13 weeks) 25. This maximum time interval is at least two times as high as the median 
time interval found in the current cohort. These time intervals seem to be reasonable in 
the light of providing treatment within a timely manner, and at the same time allowing 
an adequately broad window for scheduling SNB. As for WLE, which is often combined 
with SNB: McKenna et al. reported long term survival data of a large retrospective cohort 
showing no differences in recurrence free survival and OS regardless of the time interval 
until WLE 26. While time interval until SNB is not prognostic for survival in the current 
study, it can be used as a quality measure for hospitals performing SNB. This could form 
an addition to registration of SN positivity rate per hospital, another recently proposed 
quality measure27.
There are limitations in the current study. It is a retrospectively collected cohort from 
nine tertiary referral melanoma institutes across Europe. Inevitably, this can cause 
a selection bias, due to differences in local patient population, patient selection and 
protocols per center. As all centers are EORTC Melanoma Group centers, there is much 
expertise in work up and treatment of melanoma patients. Uniform work up of patients 
eligible for SNB, surgery and histopathological analysis of the SN was already applied 
in all these centers prior to implementation into European consensus guidelines. Local 
differences will have mainly consisted of referral policies, wait lists and case-mix rather 
than technical approaches to melanoma patients. 
In the current cohort adjuvant interferon therapy was not used as a covariate, as only a 
minority of patients received interferon in adjuvant trial setting (n=36), and for one third 
of all patients no information was available on trial participation. Primary melanomas in 
109
Timing of SNB in SN positives
6
the head and neck region seem to be underrepresented, and median Breslow thickness 
varies considerably per center. Also the number of thick melanomas is high (Table 1). 
One possible explanation for this may be the fact that all participating centers are EORTC 
Melanoma Group referral centers, with a corresponding high risk case-mix. Considering 
this, the current cohort may not be entirely representative for the general population 
that would normally be off ered a SNB. To overcome this, multivariable analyses have 
been performed to correct for known prognostic and potential confounding factors. The 
FU is limited, and an update of follow up data would defi nitely improve the value of 
the current study. During the median FU of 36 months (3 years) DFS and MSS were not 
aff ected by time interval, which is considerable. As this cohort consists of SN positive 
patients only, it is by defi nition not representative for the entire population undergoing 
SNB. It does refl ect a wide variety of SN positive patients, including patients with thin 
melanomas and patients with thick melanomas. 
Since no diff erences in survival are found for diff erent time intervals in this high risk 
SN group, survival diff erences for the more benefi cial SN negative patient population 
are unlikely. One has to take into account that although no eff ects on survival were seen 
for SN positive patients, SN-positivity rate might be adversely infl uenced by a longer 
time interval. No conclusions can be drawn on this aspect with the current SN positive 
cohort alone. 
Finally, although a fi xed maximum time interval based on survival does not seem to 
be necessary, minimizing the amount of wait time to surgery is still important to ease 
patient anxiety, as it aff ects the daily life of most patients. A survey by Eskander et al. 
in patients undergoing elective malignant thyroid surgery showed that anxiety levels 
signifi cantly decreased after surgery, suggesting that stress and anxiety levels can be 
minimalized by performing surgery timely28. Another study by Oudhoff  et al. concern-
ing surgery for benign disorders, reported an increase in negative emotional reactions 
to waiting, signifi cantly associated with wait time, which decreased signifi cantly after 
surgery29. 
Taking all of the above into consideration, the need to perform early SNB as advised 
by specifi c melanoma guidelines should be reconsidered. As there is no solid base to 
adhere to a maximum time interval between WLE and SNB as stated in the above, main-
taining a time interval falsely suggests that there still is a clinicopathological ground for 
performing SNB as soon as possible. This may facilitate unnecessary patient anxiety for 
patients on waiting lists. We therefore suggest that international melanoma guidelines 
should revise the need of a timeframe for SNB after primary melanoma excision in order 
to reduce patient anxiety and pressure on surgeon’s schedule.
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Conclusions
Time interval between primary melanoma excision and wide local excision (WLE) com-
bined with Sentinel Node Biopsy (SNB) did not influence 5-year estimated DFS and MSS 
in a population of SN positive patients. Patients who got their SNB later had a slightly 
larger disease deposit and although this may have implications for prognosis this study 
did not detect any difference. These findings indicate that it is safe and equally informa-
tive to perform SNB after a prolonged interval of >9 weeks (4th quartile). This information 
can be used to counsel patients. 
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Figure S1. 5-year estimated melanoma specifi c survival (MSS) in months stratifi ed for a time interval until 
SN biopsy of <47 days (A) and a time interval of ≥ 47 days (B) for sentinel node (SN) tumor burden catego-
ries <0.1 mm (yellow line), 0.1-1.0mm (blue line), and >1.0mm (red line) 
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Abstract
Background Patients with palpable melanoma groin metastases have a poor prognosis. 
There is debate whether a combined superficial (SGD) and deep groin dissection (CGD) 
is necessary or if SGD alone is sufficient. This study analyses risk factors for deep pelvic 
nodal involvement. 
Methods This retrospective multicenter cohort study concerned 209 therapeutic CGDs 
from four tertiary centers in the Netherlands (1992–2013), selected based on complete 
preoperative imaging and pathology reports. Analyzed risk factors included baseline 
and primary tumor characteristics, total and positive number of inguinal nodes, inguinal 
lymph node ratio (LNR) and positive deep pelvic nodes on imaging (CT ± PET, or PET - 
low dose CT). 
Results Median age was 57 years, 54% was female, median follow-up was 21 months 
(inter quartile range (IQR) 11-46 months). Median Breslow thickness was 2.10mm (IQR 
1.40-3.40mm), 26% was ulcerated. Positive deep pelvic nodes occurred in 35% of CGDs. 
Significantly fewer inguinal nodes were positive in case of negative deep pelvic nodes; 
median 1 (IQR 1-2) versus 3 (IQR 1-4) for positive deep pelvic nodes (p<0.001). LNR was 
significantly lower for negative versus positive deep pelvic nodes; median 0.15 (IQR 
0.10-0.25), versus 0.33 (IQR 0.14-0.54) (p <0.001). Combination of negative imaging, low 
LNR, low number of positive inguinal nodes and no extracapsular extension could ac-
curately predict absence of pelvic nodal involvement in 84%. 
Conclusion Patients with negative imaging, few positive inguinal nodes, no extracap-
sular extension and low LNR, have low risk of positive deep pelvic nodes and may safely 
undergo SGD alone.
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Introduction
Patients with clinically palpable nodal metastases of cutaneous melanoma in the groin 
have a poor prognosis. Balch et al. reported a 5-year overall survival (OS) rate of 59% for 
stage IIIB melanoma in the 2009 AJCC melanoma staging system analysis1. Reported 
5-year OS rates for the subgroup of patients with palpable groin metastases range from 
52% for superfi cial involvement to 12% for deep involvement2-7. 
Standard of care for these patients consists of therapeutic lymph node dissection 
(TLND)2, 8-10. There is ongoing debate, whether this should consist of either a combined 
superfi cial and deep groin dissection (CGD) or that merely a superfi cial groin dissection 
(SGD) would suffi  ce. 
Several cohort studies seem to indicate no diff erence in survival between these two 
procedures, and patients may benefi t from SGD alone if no positive deep pelvic nodes 
are present on preoperative imaging 2, 8, 10-12. 
Since the estimated prevalence of positive deep pelvic nodes in patients with palpable 
inguinal lymph nodes is 30%, the majority of patients undergoing CGD may not benefi t 
from deep groin dissection (DGD)6, 12. As CGD is a more extensive procedure than SGD, 
the risk of morbidity is potentially higher6. A clear need exists to select those patients 
who can be safely spared a DGD in absence of deep pelvic nodal involvement10, 11, 13-15. 
Preoperative imaging techniques such as CT and positron emission tomography (PET) 
form a valuable adjunct to staging. Up to 27% of patients presenting with palpable 
lymph node metastases have synchronous distant metastases at preoperative PET/
CT, which changes the indication for surgery into palliative resection and/or systemic 
therapy16. Additionally, imaging provides assessment of suspicious deep pelvic nodes 
prior to surgery. High positive (PPV) and negative predictive value (NPV) have been 
achieved by Allan et al, (100% and 86% respectively)3. Other series reported PPV and 
NPV of 40-60%, which is too low to confi rm or reject presence of positive deep pelvic 
nodes based on preoperative imaging alone2, 17, 18. Once suspicious deep pelvic nodes are 
detected on preoperative imaging, one cannot ignore their presence, and CGD is highly 
recommended. Absence of suspicious deep pelvic nodes on imaging does not rule out 
deep pelvic nodal involvement. Once imaging has been performed the focus should be 
on identifi cation of further risk factors for positive deep pelvic nodes2, 7, 11, 15, 17-21. 
Aim: to analyze risk factors for deep pelvic nodal involvement in a retrospective mul-
ticenter cohort of palpable groin melanoma metastases. This could aid in the develop-
ment of an algorithm for selective surgery in the future.
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Patients and Methods
Patients
This retrospective multicenter cohort study describes 209 therapeutic CGDs performed 
at four tertiary melanoma centers in the Netherlands between 1992 and 2013. Patient 
selection was based on presence of a palpable nodal metastasis to the groin, complete 
pathology reports of the performed CGD, (i.e. clearly describing the dissected lymph 
nodes as inguinal or iliac, including obturator area), and preoperative imaging (CT, PET 
or PET/CT). Patients without imaging, with prior lymph node dissections in the groin 
area or with isolated limb perfusion or positive sentinel node(s) as indication for CGD 
were excluded. Analyzed preoperative imaging modalities were: CT scan, PET, and com-
bined PET with low dose CT (PET-CT). 
All patient characteristics were obtained from medical records and collected in 
a database for the current retrospective multicenter cohort study, according to local 
institutional review committee guidelines and national legislation. 
Surgical Procedure
CGD was performed either via two separate transverse incisions, or via an inguinal el-
lipse shaped incision extending cranially according to local preferences per center, as 
described in detail elsewhere6, 22. 
Pathology
CGD pathology reports were considered adequate when clear description was given of 
the total number of inguinal nodes, as well as the number of tumor positive inguinal 
nodes, and similar description was given of the number of dissected deep pelvic nodes 
(iliac nodes and obturator nodes) and the number of tumor positive deep pelvic nodes. 
Statistics / Data analysis 
Patients were divided into two categories based on deep pelvic nodal status: positive or 
negative. Univariable Chi-squared tests were performed to test for significant differences 
in prevalence of gender, primary tumor located on the trunk, primary tumor stage (T1-T4), 
ulceration, and inguinal extracapsular extension (ECE). Nonparametric tests were performed 
to test for differences in age, median Breslow thickness, total number of inguinal nodes and 
number of positive inguinal nodes, total number of excised nodes and number of positive 
nodes, total number of deep pelvic nodes, number of positive deep pelvic nodes, and LNR. 
Sensitivity, specificity, PPV, NPV, and accuracy were calculated for all imaging modalities using 
number of true positives (TP), false positives (FP), true negatives (TN) and false negatives (FN). 
Differences in baseline characteristics were tested with univariable logistic regression 
analysis. Multivariable models were calculated using variables significant at univariable 
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analysis. Binary logistic multivariable regression analyses were performed to test for 
independent predictors of deep pelvic nodal involvement.
Ridge regression analysis was performed to exclude the infl uence of multicollinearity 
in a prediction model based on independent predictive variables. An area under the 
receiver operating characteristic curve (AUC) was calculated for the model. The AUC 
indicates the probability that patients with observed positive deep pelvic nodes had a 
higher predicted probability than patients with observed negative deep pelvic nodes, 
providing information about the predictive value of the model.
All statistical analyses except Ridge regression were performed using SPSS Version 
21.0 (IBM Corp. Released 2012. Armonk, NY, United States). Ridge regression was per-
formed using RStudio (RStudio Inc. Boston, Massachusetts, United States). An α < 0.05 
was considered signifi cant.
Results
Patients
Table 1 gives an overview of baseline characteristics. The majority of patients (n=201, 
96%) had palpable stage IIIB disease, eight patients (4%) had stage IV disease. Median 
Breslow thickness was 2.10 mm (IQR 1.4 - 3.4 mm). Twelve patients had a history of nega-
tive sentinel node. Median follow-up was 21 months (IQR 11 - 46 months). 
Imaging and Pathology
Four patients underwent both CT and PET/CT, they were scored as PET/CT since the 
additional information obtained from PET/CT was used for fi nal determination of clinical 
nodal status. Predictive accuracy per imaging modality is shown in table 2. The diff erent 
imaging modalities were used equally between the two groups (i.e. positive or negative 
deep pelvic nodes). 
Logistic regression analysis
Variables signifi cantly diff erent on univariable analysis (table 1) were included in multi-
variable binary logistic regression analyses. LNR and number of positive inguinal lymph 
nodes were assessed in separate models due to evident multicollinearity. Remaining sig-
nifi cant independent predictors were: suspicious deep pelvic nodes on imaging (odds 
ratio (OR) 9.64, 95% CI 4.35 – 21.3, p < 0.001), increasing LNR (OR 34.2, 95% CI 5.47 – 214, 
p < 0.001), presence of ECE (OR 2.13, 95% CI 1.01 – 4.48, p = 0.046), and in a separate 
multivariable model without LNR: increasing number of positive inguinal lymph nodes 
(OR 1.27, 95% CI 1.06 – 1.53, p = 0.010). 
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Table 1. Baseline Characteristics.
Characteristic Total 
n=209 (100%)
Pelvic Nodes - 
n=135 (65%) 
Pelvic Nodes +
n=74 (35%) 
P
n,(%) n, (%) n, (%)
Gender
Female 114 (54) 76 (56) 38 (51)  
Male 95 (46) 59 (44) 36 (49) 0.49 
Age (yrs) median (IQR) 57 (45 - 65) 55 (46 - 65) 59 (44 - 65) 0.63
Center
1 60 (29) 42 (31) 18 (24)  
2 57 (27) 38 (28) 19 (26)  
3 24 (12) 11 (8) 13 (18)  
4 68 (32) 44 (33) 24 (32) 0.21 
Tumor stage
T1 22 (11) 9 (7) 13 (18)  
T2 57 (27) 36 (27) 21 (28)  
T3 60 (29) 39 (29) 21 (28)  
T4 30 (14) 22 (16) 8 (11)  
Unknown primary 10 (5) 8 (6) 2 (3)  
Missing 30 (14) 21 (15) 9 (12) 0.16 
Ulceration
Absent 125 (60) 74 (55) 51 (69)  
Present 54 (26) 38 (28) 16 (22)  
Missing 30 (14) 23 (17) 7 (9) 0.16 
Clark level**
II 1 (0.5) 0 (-) 1 (1)  
III 35 (17) 22 (16) 13 (17)  
IV 84 (40) 54 (40) 30 (41)  
V 13 (6) 11 (8) 2 (3)  
Missing 76 (36.5) 48 (36) 28 (38) 0.29 
Location
Leg 166 (80) 106 (79) 60 (81)  
Trunk 28 (13) 17 (13) 11 (15)  
Unknown primary 10 (5) 8 (6) 2 (3)  
Missing 5 (2) 4 (3) 1 (1) 0.62 
Histology
SSM 67 (32) 44 (32) 23 (31)  
NM 37 (18) 28 (21) 9 (12)  
Other 15 (7) 9 (7) 6 (8)  
Unknown primary 10 (5) 8 (6) 2 (3)  
Missing 80 (38) 46 (34) 34 (46) 0.24 
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Subgroup analysis negative imaging
Suspicious deep pelvic nodes on imaging were highly predictive for positive deep pelvic 
nodes. A subgroup of 155 patients without suspicious deep pelvic nodes on imaging 
was selected for further analysis of additional risk factors for positive deep pelvic nodes. 
Thirty-fi ve of these patients (23%) had positive deep pelvic nodes at histopathological 
examination with H&E staining, i.e. imaging was false negative. Univariable analysis 
results are displayed in table 3. Multivariable analysis was performed including all 
Table 1. Baseline Characteristics. (continued)
Characteristic Total 
n=209 (100%)
Pelvic Nodes - 
n=135 (65%) 
Pelvic Nodes +
n=74 (35%) 
P
n,(%) n, (%) n, (%)
№ nodes, median (IQR)
Inguinal 10 (7 - 13) 10 (7 - 13) 9 (7 - 12) 0.54 
Deep  6 (4 - 10)  6 (4 - 9)  8 (5 - 11)  0.039* 
Total 17 (13 - 22) 17 (13 - 21) 17 (14 - 22) 0.39 
№ positive nodes, median (IQR)
Inguinal 2 (1 - 3) 1 (1 - 2) 3 (1 - 4) <0.001* 
Deep  0 (0 - 1)  0 (0)  2 (1 - 3)  <0.001* 
Total 2 (1 - 4) 1 (1 - 2) 5 (3 - 7) <0.001* 
LNR
median (IQR) 0.20 (0.11 - 0.33) 0.15 (0.10 - 0.25) 0.33 (0.14 - 0.54) <0.001* 
Inguinal ECE 
No 134 (64) 94 (70) 40 (54)  
Yes 75 (36) 41 (30) 34 (46) 0.025* 
n, number of patients; P, p-value; yrs, years; IQR, inter quartile range; T1, Breslow <1.00mm; T2, Breslow 1.01-
2.00mm; T3, Breslow 2.01-4.00mm; T4, Breslow >4.00mm; №, number of; LNR, inguinal lymph node ratio; 
ECE, extracapsular extension. 
*signifi cant, p<0.05. Calculated with Chi-square and non-parametric tests ** Clark level II and III were combined 
for Chi-Square test.
Table 2. Identifi cation of Positive Deep Pelvic Lymph Nodes Using Preoperative Imaging Techniques 
(n=209).
CT (n=67) CT and/ or PET (n=57*) PET/CT (n=85**)
Sensitivity 57% 36% 61%
Specifi city 93% 94% 83%
PPV 80% 73% 68%
NPV 83% 70% 79%
Accuracy 82% 70% 75%
Abbreviations: CT, computed tomography; PET, position emission tomography; PET/CT, combined PET and 
low dose CT; PPV, positive predictive value; NPV, negative predictive value.*; 13 patients underwent PET 
alone. **, 4 patients underwent separate CT as well.
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Table 3. Baseline Characteristics for patients with negative preoperative imaging.
Characteristic Total 
(n=155)
Pelvic nodes –
(n= 120)
Pelvic nodes + (n= 35) P
n (%) n (%) n (%)  
Gender  
Female 83 (54) 67 (56) 16 (46)  
Male 72 (46) 53 (44) 19 (54) 0.29
Age (yrs) median (IQR) 56 (45 - 64) 55 (46 - 65) 57 (44 - 64) 0.99
Center  
1 44 (28) 38 (32) 6 (17)  
2 48 (31) 35 (29) 13 (37)  
3 18 (12) 10 (8) 8 (23)  
4 45 (29) 37 (31) 8 (23) 0.17
Breslow median (IQR) 2.10 (1.40 - 3.25) 2.20 (1.45 - 3.55) 1.90 (1.15 - 2.80) 0.11
Tumor stage  
T1 14 (9) 8 (7) 6 (17)  
T2 45 (29) 33 (28) 12 (34)  
T3 44 (28) 37 (31) 7 (20)  
T4 23 (15) 19 (16) 4 (11)  
Unknown primary 9 (6) 7 (6) 2 (6)
Missing 20 (13) 16 (13) 4 (11) 0.38
Ulceration  
Absent 90 (58) 67 (56) 23 (66)  
Present 44 (28) 36 (31) 8 (23)  
Missing 21 (14) 17 (13) 4 (11) 0.34
Clark level**  
II 1 (0.6) 0 (-) 1 (3)  
III 25 (16) 20 (17) 5 (14)  
IV 65 (42) 49 (41) 16 (46)  
V 11 (7) 11 (9) 0 (-)  
Missing 53 (34) 40 (33) 13 (37) 0.070
Location  
Leg 118 (76) 93 (78) 25 (71)  
Trunk 23 (15) 16 (13) 7 (20)  
Unknown primary 9 (6) 7 (6) 2 (6)  
Missing 5 (3) 4 (3) 1 (3) 0.81
Histology  
SSM 52 (34) 40 (33) 5 (14)  
NM 31 (20) 26 (22) 12 (34)  
Other 10 (6) 8 (7) 2 (6)  
Unknown primary 9 (6) 7 (6) 2 (6)  
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signifi cant variables assumed to be predictive for deep pelvic nodal status; number of 
positive inguinal nodes, LNR and ECE status. Evident multicollinearity was observed. 
To overcome this problem a predictive Ridge logistic regression analysis was per-
formed. Only LNR remained as signifi cant independent predictor for positive deep 
pelvic nodes (p = 0.014). Number of positive inguinal lymph nodes and ECE were chosen 
to remain in the model as contributing covariates as these were thought to be of sub-
stantial additional clinical relevance. A receiver operating characteristic (ROC) curve of 
the predicted probabilities for positive deep pelvic nodes was created, displaying a fair 
AUC of 0.72 (AUC values range between 0 and 1, where high scores are indicative of high 
accuracy) (Figure 1). 
The optimum cut-off  value for the predicted probability of the model (i.e. the prob-
ability at which the model outcome correctly identifi es an observed positive patient 
as positive) was chosen based on high specifi city, in order to minimize false negative 
outcomes. Corresponding probability cut-off  value and sensitivity were deduced from 
the ROC curve. For a specifi city of 90%, the cut-off  value for a positive test outcome was 
a probability for positive deep pelvic nodes of 32% or more. Sensitivity was 43%, PPV 
was 50%, NPV 84%, and overall accuracy of this model was 77%.
Table 3. Baseline Characteristics for patients with negative preoperative imaging. (continued)
Characteristic Total 
(n=155)
Pelvic nodes –
(n= 120)
Pelvic nodes + (n= 35) P
n (%) n (%) n (%)  
Missing 53 (34) 39 (32) 14 (40) 0.86
№ nodes, median (IQR)
Total 17 (13 - 21) 17 (13 - 21) 17 (14 - 22) 0.42
Inguinal 10 (8 - 12) 10 (8 - 13) 9 (8 - 12) 0.69
Deep 6 (4 - 9) 6 (4 - 9) 7 (4 - 11) 0.15
№ positive nodes, median (IQR)
Total 2 (1 - 4) 1 (1 - 2) 5 (3 - 6) <0.001*
Inguinal 1 (1 - 3) 1 (1 - 2) 3 (1 - 4) <0.001*
Deep 0 (0) 0 (0) 2 (1 - 2) <0.001*
LNR, median (IQR) 0.17 (0.11 - 0.31) 0.21 (0.10 - 0.25) 0.33 (0.13 - 0.50) 0.001*
ECE inguinal
No 96 (62) 79 (66) 17 (49)  
Yes 59 (38) 41 (34) 18 (51) 0.075
n, number of patients; P, p-value; ; yrs, years; IQR, inter quartile range; T1, Breslow <1.00mm; T2, Breslow 
1.01-2.00mm; T3, Breslow 2.01-4.00mm; T4, Breslow >4.00mm; №, number of; LNR, inguinal lymph node 
ratio; ECE, extracapsular extension.
*, signifi cant (p<0.05) ** for Chi-Square test Clark II & III were combined
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Discussion
In this CGD cohort 35% of all patients have deep pelvic nodal involvement, which is in 
line with the literature10, 11, 13-15. This study analyses risk factors to identify deep pelvic 
nodal involvement. Imaging is a strong predictor. Our prediction model might lower the 
rate of CGD without positive pelvic nodes and minimizes the number of false negative 
outcomes after imaging.
Imaging
The imaging modalities used in this study are fair in correctly predicting positive deep 
pelvic nodes. Still a considerable number of patients have false positive imaging (20-
32%). We can only speculate on the possible causes of false positive imaging. This might 
be partially explained by a small group of patients undergoing diagnostic excision 
biopsy of the palpable lymph node prior to imaging. This might cause a lymph node 
enlargement in the pelvic area. Another cause may be the inevitable interobserver vari-
Figure 1. ROC curve for prediction model probability positive deep nodes. 
ROC; receiver operator characteristics.
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ability in radiology. Improvement of imaging techniques over time may have altered the 
number of false positive lymph nodes detected during the present study period. 
NPVs of the preoperative imaging techniques performed in the current study range 
between 70% and 83%, leaving a substantial proportion of 23% (17-30%) of patients to 
be falsely diagnosed with negative deep pelvic nodes. Several studies have reported 
on NPV of CT, and although high NPVs have been described by Allan et al, and Van der 
Ploeg et al., overall reported values range considerably 2, 3, 6, 17, 18. Ongoing development 
of the newest imaging techniques such as use of a melanoma specifi c PET tracer ([18F]
ICF01006) may enhance the accuracy of imaging and subsequently decrease the FN 
rate23.
Predictive factors
Predictive factors for deep pelvic nodal involvement found in the current study are ingui-
nal nodal status as defi ned by the number of positive inguinal nodes and LNR, inguinal 
ECE, and suspicious deep pelvic nodes on preoperative imaging, which is concordant 
with the literature 2, 7, 11, 15, 17-21. These risk factors may be applied to select patients for 
SGD in addition to imaging without suspicious deep pelvic nodes. A hypothetical two 
stage approach would be: when preoperative imaging is negative, patients fi rst undergo 
solely an SGD. The pathology results can then be used to determine the risk of occult 
positive deep pelvic nodes, and a decision can be made on whether to perform an ad-
ditional DGD or not. The fact that patients must undergo two separate operations is a 
drawback, but this way, a DGD can be spared in 126 out of all patients (60%). 
Patient Selection
Standard CGD for palpable stage III melanoma shows that 135 out of 209 deep pelvic 
groin dissections (65%) have been performed in the absence of pelvic nodal metastases. 
Use of pre-operative imaging alone for selection between CGD and SGD would reduce 
the number of CGDs from 209 to 54. The remaining 155 patients would undergo SGD 
alone. Thirty-fi ve of these 155 patients undergoing SGD alone are false negative (FN rate 
23%), and would be possibly undertreated (i.e. undergoing no DGD). 
Better patient selection is necessary in the negative imaging group, as potential 
decrease in the number of false negatives will make patient selection safer. This formed 
the rationale for the prediction model, which is based on 153 patients* (155 - 2 patients, 
*missing data) with negative imaging. Using this model 124 out of 153 patients would 
undergo SGD alone, and FN rates would be reduced to 20 out of 124 patients (FN rate 
16%). 
Concluding, this model forms an adjunct to the use of preoperative imaging as selec-
tion tool for SGD or CGD, both drastically minimizing the number of patients without 
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affected pelvic nodes undergoing a DGD, and controlling the number of patients with 
affected pelvic nodes potentially being undertreated by not undergoing a DGD.
The 16% FN rate of this model is still considerable. Although surgery forms the 
cornerstone of melanoma treatment, one may question the role of DGD in the current 
era of upcoming effective systemic treatments. On one hand, the majority of patients 
undergoing standard CGD for palpable groin metastases have negative deep pelvic 
nodes. On the other hand, there is evidence to assume that positive deep pelvic nodes 
may merely be a biomarker for stage IV disease, as survival rates depend on deep pelvic 
nodal status rather than extent of surgery 6, 8, 11, 12, 15. Khosrotehrani and Van der Ploeg 
presented a nomogram for prediction of prognosis in stage III B/C melanoma patients, 
using pathology results and age24. Application of this nomogram could further aid in 
selecting patients for SGD alone. Another preoperative aid besides the presented model 
could be use of the biomarker S-100B. As Kruijff et al. have shown, high serum levels of S-
100B are associated with a significantly lower DFS and a trend towards worse melanoma 
specific survival (MSS), indicating its potential as a biomarker for clinically occult stage 
IV disease 25, 26. Patients with low risk of deep pelvic nodal involvement and low S-100B 
could then undergo SGD alone, with regular control visits to detect early signs of deep 
pelvic nodal involvement (suspicious nodes on imaging/elevated S-100B). Bearing this 
in mind, the 16% FN rate of the presented prediction model may be allowable. 
Limitations 
This study is retrospective and is spread over a long timeframe. This entails inevitable 
alterations and improvement of imaging techniques and clinical practice over time, 
affecting our results. The prediction model designed for the current study has not been 
validated internally, due to a small sample of patients with positive deep pelvic nodes. 
It has to be pointed out that this model in its current state is not suited for clinical use, 
as there is still much to be gained from further development and testing. A prospective 
multicenter registration study is planned to be performed, enabling adequate data col-
lection on all patients undergoing CGD for palpable groin metastases within a relatively 
small time frame. Cross validation of the presented prediction model will be performed, 
and its role in future clinical practice will be further defined. With the proposed prospec-
tive study, accuracy of imaging techniques can be determined more adequately.
 Concerning the possible additional morbidity of a DGD; although to date no prospec-
tive randomized controlled trial (RCT) has been performed to address this, evidence ex-
ists that the additional morbidity of DGD in a CGD might be more limited than has been 
described in the past.6, 22 The recently opened Australia and New Zealand Melanoma 
Trials Group 01.12 EAGLE FM Trial (clinicaltrials.gov identifier: NCT02166788) will hope-
fully provide an answer to this question. This multicenter RCT compares SGD and CGD 
for melanoma patients with groin metastases and no suspicious PET/CT scan. 
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As operating time is generally longer in a CGD, there is a potentially higher risk of 
surgical site infections. In a large retrospective series of Glarner et al. the number of 
surgical site infections is indeed signifi cantly higher for CGDs, with an adjusted odds 
ratio of 2.627. Once again, to gain more insight in the actual diff erences in morbidity 
between SGD and CGD, we will have to await results from the EAGLE FM Trial. 
Concluding, high LNR, high number of positive inguinal nodes and inguinal ECE are 
risk factors for positive deep pelvic nodes in patients with palpable groin metastases of 
cutaneous melanoma. To date, accurate prediction of deep pelvic nodal status is subop-
timal still, hence reliable selection of patients who can be spared a DGD remains diffi  cult. 
Combined use of preoperative imaging and a preliminary prediction model based on 
histopathology results of the inguinal (superfi cial) part of CGD could accurately predict 
negative deep pelvic nodes in up to 84%. Thereby potentially identifying a group of low 
risk patients, in whom the extent of surgery might safely be minimized. The risk fac-
tors and the prediction model will be further investigated in a prospective multicenter 
registry trial for CGDs. 
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General Discussion
Breslow thickness is the most powerful prognostic feature for primary cutaneous 
melanoma’s, closely followed by ulceration1. Presence of nodal metastases is another 
major discriminator in the American Joint Committee on Cancer (AJCC) staging system, 
dividing patients between stage I or II (no nodal involvement) and stage III (regional 
nodal involvement or in transit metastases). Finally, stage IV is defi ned by the presence 
of distant nodal involvement and/or visceral metastases1. 
Nodal Staging
There is abundant evidence that nodal metastases in melanoma patients equal poor 
survival1, 2. In clinically node negative patients, sentinel node biopsy (SNB) has proven to 
be a highly discriminative nodal staging tool to further diff erentiate between patients 
with a good prognosis (sentinel node (SN) negative) and patients with a less favorable 
prognosis (SN positive)3, 4. As there is no proven therapeutic eff ect for survival by per-
forming a SNB, it is important to critically reassess the potentially negative aspects of 
this minimally invasive, albeit invasive nonetheless, surgical staging procedure. 
While universally recommended as a staging procedure, not all eligible melanoma 
patients undergo SNB. This is unlike the practice in other malignancies such as breast 
cancer. There are several explanations for this discrepancy between guideline recom-
mendations and clinical practice, namely the absence of solid evidence regarding 
therapeutic eff ect on survival5, discrepancies in local health care reimbursements6, 7, and 
socio-economic status8.
In the following paragraphs the indication for SNB is discussed, as well as potential 
minimally invasive alternatives.
First, recommendations on the indication for SNB will be re-evaluated here. SNB is 
generally advised for intermediate and thick melanomas: i.e. >1.00mm – 4.00mm or 
>4.00mm with or without ulceration9, 10. In melanomas <1.00mm the risk of a positive 
SN is minimal, thus standard SNB is not recommended9. Although melanoma survival for 
thin melanomas (Breslow thickness <1mm, pT1) is excellent, it does not equal 100%. This 
is due to a minority of patients who will develop metastases over time and ultimately die 
due to melanoma1, 11. As the majority of currently diagnosed new cutaneous melanomas 
consists of thin melanomas (Breslow thickness <1mm, pT1) without clinically evident 
lymph node metastases1, 12, 13, additional risk factors have been investigated in order to 
select those patients who have a high risk of developing nodal metastases, in order to 
consider SNB for this subgroup as well. As described in detail in Chapter 2, several pri-
mary tumor features have served as high risk feature, being ulceration (AJCC 6th and 7th 
edition) high Clark level (IV or V, AJCC 6th edition), or mitotic rate of ≥1 mitosis/mm2 (AJCC 
7th edition)1, 14. Since the implementation of the 7th edition AJCC staging system virtually 
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all melanoma guidelines adopted the recommendation to consider SNB for high risk 
thin (pT1b) melanomas9, 15, 16. Chapter 2 reports on the effects of these changes in SNB 
recommendation in the Dutch pT1 melanoma population. No increase in SN positivity 
rate occurred in this group of patients, remaining <10%. It is questionable whether a 
surgical staging procedure is the optimal way to go to confirm that 90% of pT1b patients 
are node negative.
Thick melanomas (pT4) pose a different challenge. Since Breslow thickness and ul-
ceration are the main prognostic features in primary melanoma, and ulceration occurs 
more often in thicker melanomas, patients with a pT4 melanoma have an a priori worse 
prognosis than intermediate thickness melanomas, regardless of their nodal status. 
They form the grey zone between stage II and stage III as was illustrated by Balch et al. in 
the 7th edition of the AJCC staging system1. Thus it is questioned whether nodal staging 
with SNB adds any substantial information on prognosis in pT4 patients. Nevertheless, 
several studies have shown that SNB is an accurate discriminator for prognosis in this 
group as well3, 17, 18. 
Next to reassessment of the indication for SNB, minimally invasive alternatives deserve 
further attention. Chapter 3, 4, and 5 provide varying methods of combined ultrasound 
(US) and FNAC for non-operative examination of the SN. In Chapter 3 a new US mor-
phology criterion is presented; the echo free island (EFI). While an infrequent finding 
in US assessment of the SN, it is associated with presence of peripheral perfusion (PP), 
another US criterion. Five-year melanoma specific survival was worse for patients with 
EFI: 80% versus 92% when absent. EFI is found to be a discriminatory US morphology 
sign which can be useful for early identification of SN metastases in melanoma patients. 
Chapter 4 describes the long-term survival results of combined US and FNAC prior to 
SNB in 1,000 patients. Survival analyses demonstrated that patients with positive US-
FNAC had poor survival. Patients with suspicious US and negative FNAC and patients 
with normal US had comparable survival. A step-wise approach to melanoma patients 
is supported by these results: in case of a positive FNAC and/or clearly malignant US 
finding patients can be spared a SNB and be offered a lymphadenectomy instead. In 
case of suspicious US and negative FNAC, patients could be offered continued US sur-
veillance or SNB for higher risk primary tumors. Completely US-FNAC negative patients 
might only require follow-up and no SN staging, with continued US surveillance as 
addendum for high risk T3/4 and/or ulcerated primaries. In Chapter 5 an overview of 
the literature on ultrasound assessment of the SN is presented, as well as a pilot and 
study protocol for Gamma probe and ULtrasound guided Fine needle aspiration cytol-
ogy of the sentinel node Trial (GULF trial). The literature on pre-operative assessment of 
regional lymph nodes with US in clinically N0 melanoma patients is disparate. Targeted 
US-FNAC or other new techniques have the potential to replace SNB in the future, how-
ever, the reported findings need to be replicated in prospective clinical trials. A pilot 
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with gamma probe guided US-FNAC shows accurate SN identifi cation in up to 90% of 
patients. The presented GULF trial study protocol may provide potential improvement 
to the reported US-FNAC techniques, and ultimately may become a possible replace-
ment of the SNB. While none of the abovementioned procedures have reached the 
accuracy of the surgical SNB yet, further tailoring of these techniques may change that 
situation and lead to minimally invasive assessment of SN status. Simultaneously, other 
minimally invasive techniques have been developed and are currently being tested in 
clinical trial setting; for instance sonoelastography19, 20 and multispectral optoacoustic 
tomography21, addressed in Chapter 5. Based on the currently available evidence, nodal 
staging in clinically node negative patients is worthwhile for patients with a Breslow 
thickness of >1mm, considering that below this Breslow thickness the risk of a positive 
SN is less than 10%. Since all SN positive patients may potentially benefi t from adjuvant 
immunotherapy, performing SNB in thick melanomas (>4mm) can be justifi ed as well.
Thirdly, the approach of nodal staging in daily clinical practice requires re-evaluation. 
The decision on whether there is an indication for SNB should be made by a well in-
formed and experienced doctor, preferably a melanoma surgeon or - dermatologist. The 
next question is when to perform SNB. Ideally this is done as soon as possible, in order to 
provide information on prognosis to the patient in a short period of time after the initial 
melanoma diagnosis. The current Dutch melanoma guideline even poses a strict time 
limit for SNB to be performed within 6 weeks, suggesting a potential detrimental eff ect 
if not complied with, without evidence to support this cut-off 22. 
Considering the fact that there is a global increase in melanomas, and general 
practitioners and dermatologists increasingly tend to perform high urgency referrals, 
increased pressure on wait lists can be expected. Potential eff ects of SNB timing, and 
subsequently completion lymph node dissection (CLND) timing in case of positive SNs 
were investigated in Part II of this thesis. No diff erence in recurrence free survival or 
melanoma specifi c survival was found for SN positive patients (Chapter 6), or SN nega-
tive patients (Chapter 7), nor a diff erence in SN positivity rates (Chapter 7). Timing of 
CLND was also not relevant for survival in the cohort investigated in Chapter 8. While 
these are all retrospective studies, they provide evidence that a small variation in timing 
of SNB or CLND is not detrimental for survival, which can be used in shared decision 
making. One potential explanation for these fi ndings could be that the time interval 
investigated is too narrow for any time dependent eff ect to become apparent. For 
instance if a time interval of > 1 year was compared with instant SNB or CLND, there 
might have been a diff erence in survival. This was the subject of MSLT I and DeCOG 
respectively. Neither of these studies showed a signifi cant diff erence in survival for im-
mediate SNB (and CLND in case of positive SN) versus nodal observation (MSLT I) or im-
mediate CLND versus nodal observation (DeCOG)3, 23. Another explanation may be that 
lymphatic metastases occur already at a very early point in melanoma development and 
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progression; and that lymphatic metastases may be present for years prior to melanoma 
diagnosis, but are growing very slowly due to suppression by the immune system24. In 
this case, variation in time interval between primary melanoma excision and SNB and/
or CLND of a few weeks may be irrelevant compared to the previous years of melanoma 
development. 
The prognostic value of SN tumor burden poses a paradox here, as maximum SN 
tumor diameter is clearly associated to survival25, 26. Potentially our immune system is ca-
pable to contain growth of very small micrometastases (i.e. <0.1mm), but once a certain 
threshold size has been reached, the proliferative and invasive nature of the lymphatic 
metastases may overrule the suppressing capabilities of the immune system24, leading 
to further growth and perhaps to simultaneous accelerated growth of micrometastases 
at distant sites as well. Kakavand et al. have found that patients with tumoral PD-L1 
expression in the sentinel node had a median larger maximum SN tumor burden, which 
may be an explanation for acquired anti-tumor immunity evasion by the tumor27. The 
threshold at which anti-tumor immunity fails may be size dependent, time dependent, 
age and gender dependent, and probably dependent on many other patient and tumor 
characteristics; but what is mainly important is that in our daily clinical practice nodal 
(staging) surgery does not need to be performed in a fortnight after diagnosis. 
Lymphadenectomy for microscopic stage III– necessary?
As mentioned in Chapter 1 the MSLT 1 did not show an overall survival benefit for SNB 
(plus CLND in case of a positive SN) compared to patients who underwent WLE alone3. 
Following the results of MSLT 1, the MSLT 2 investigates whether omission of a CLND 
in SNB positive patients causes any difference in survival outcomes28. While final results 
from the MSLT 2 are still awaited, recently Leiter et al. published the first results of the 
DECOG trial, in which SN positive patients either underwent CLND or nodal observation 
with repeated ultrasound imaging23. This study showed no survival benefit for CLND at 3 
year follow-up. While the study was underpowered due to lower than expected accrual 
rate, and patients with low SN tumor burden were overrepresented, the fact that there 
was absolutely no survival difference at 3 years suggests that a survival benefit from 
CLND is unlikely to be expected. Final results from the MSLT 2 will have to be awaited, as 
this study has included a larger number of patients with longer follow-up, and thus will 
be able to provide more information on the possible therapeutic value of CLND. 
Meanwhile, daily clinical practice already differs substantially from guideline rec-
ommendations. Despite that CLND is still ubiquitously recommended for SN positive 
patients pending the final study results on its therapeutic value9, 15, 16, 28, not all patients 
actually undergo CLND. Bilimoria et al reported that only 50% of the SN positive mela-
noma patients in the United States of America had a CLND29, which is in line with results 
from the worldwide survey performed by Pasquali et al30. It is not known whether the 
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decision to not undergo CLND is generally patient driven or physician driven, but these 
studies clearly demonstrate that there can be a signifi cant disparity between guideline 
recommendations and actual daily clinical practice. 
Extent of surgery for macroscopic stage III (lymphadenectomy)
Finally, surgery for clinically nodal positive patients is again a diff erent story altogether. 
The role of lymph node dissection is threefold in these patients: to achieve regional 
control; to provide more detailed prognostic information based on the number of in-
volved lymph nodes and presence of extracapsular extension, and to achieve curation 
in a certain proportion of patients. It is universally recommended as standard proce-
dure9, 15, 16. An aggressive surgical approach may seem appropriate to achieve maximal 
regional control and potentially therapeutic benefi t, but risk of potentially signifi cant 
surgical morbidity is increased due to the presence of enlarged or even giant bulky 
or matted nodes, which may increase surgery time and risk of hemorrhage and infec-
tions31, 32. In a prospective morbidity analysis of the MSLT I no signifi cant diff erences in 
short term morbidity were found between CLND and delayed LND, although there was 
a higher percentage of wound separation, seroma/hematoma, and hemorrhage in the 
delayed group33. Another consequence of radical lymph node dissection is the frequent 
development of chronic lymph edema; this occurred signifi cantly more often in delayed 
LNDs than in CLND (20% vs. 12%)33. Less extensive surgery may limit these negative 
eff ects. This is relevant especially in patients with positive groin lymph nodes, which 
have a higher complication rate than patients with axillary or head and neck lymph 
node involvement31, 33. There is no uniform approach to patients with groin lymph node 
metastases; either a combined superfi cial and deep lymph node dissection is performed 
removing all inguinal, iliac and obturator nodes; or a superfi cial inguinal lymph node dis-
section is performed removing only inguinal lymph nodes. Since only 30% of removed 
pelvic (iliac and obturator) nodes are positive after a combined groin dissection, this 
approach may be too radical, as there is no uniform evidence that standard removal of 
pelvic nodes improves survival34-39. Chapter 9 provides a two-step approach for patients 
with palpable groin lymph node metastases in order to safely minimize the number of 
negative pelvic lymph node dissections. Considering the low OS rates for patients with 
pelvic nodal involvement34, patients with a high risk of pelvic nodal involvement may 
ultimately be spared an additional pelvic groin dissection as well. Instead they can be 
off ered systemic targeted therapy or immunotherapy, since this has shown to improve 
survival in irresectable stage III and stage IV melanomas2. 
Systemic Therapy and Future Perspectives
Adjuvant treatment of high risk stage II/III disease with anticancer vaccines were not 
eff ective or even harmful40, and interferon alfa has shown to only have a marginal eff ect 
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on relapse free survival, but not on overall survival in the entire group41-43. Trials with 
pegylated interferon alfa did show a survival benefit, but only for microscopic stage III 
disease in ulcerated primaries44-46.
Recently, immunotherapy has led to a breakthrough in the adjuvant treatment of 
stage III melanoma. Ipilimumab, a selective CTLA4 checkpoint inhibitor, can inhibit im-
mune tolerance and thus might cause regression of tumor cells, as was reflected in im-
proved stage IV survival47. In the adjuvant ipilimumab trial by the EORTC (EORTC 18071) 
a significant survival benefit was demonstrated (hazard ratio 0.76, 95% confidence 
interval 0.64-0.89, p<0.001)48. Grade III to IV immune related adverse events occurred 
in 41.6% in the ipilimumab group, and five patients (1.1%) died due to immune related 
adverse events. These results will have to be validated in order to adequately value the 
costs of these side effects versus the gains in terms of recurrence free and melanoma 
specific survival, but so far, results are promising. This trial has opened the gateway for 
other studies investigating checkpoint blockade treatment in the adjuvant setting for 
melanoma and other types of cancer. The results of the EORTC 1325, which investigates 
pembrolizumab (PD-1 checkpoint inhibitor) are currently awaited, as full accrual was 
reached in October 2016. Molecular targeted therapy is currently studied as adjuvant 
treatment as well, for instance in the COMBI-AD trial, which compares simultaneous use 
of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) versus placebo for high 
risk BRAF V600 positive melanoma patients. It has reached full accrual in December 2014 
and is awaiting analyses. 
In the near future, minimally invasive alternatives to the SNB such as US or MSOT21 
guided FNAC will be implemented in standard care, and ultimately will replace surgical 
SNB as we know it. Nevertheless, nodal staging has become increasingly important in 
the light of adjuvant systemic therapy with checkpoint inhibitors or combined targeted 
therapy. Thus an initial increase in the number of performed SNBs can be expected 
in the coming years. The same may be true for CLND; depending on entry criteria for 
upcoming adjuvant trials. A next step would be to randomize between SNB only and 
adjuvant therapy versus SNB plus CLND and adjuvant therapy; considering the fact that 
only 20% of SN positive patients have additional positive non-SNs. The role of melanoma 
surgery thus may become more limited in stage III disease. At the other hand patients 
with previously irresectable stage III or IV disease may become suitable candidates for 
surgery after successful treatment with either checkpoint inhibitors or BRAF- and/or 
MEK-inhibitors, as is currently being investigated in a phase-II setting in the REDUCTOR 
trial49. 
Melanoma has claimed many lives and will sadly continue to do so, but finally time 
seems to be on our side. When once aggressive radical surgery was the only available 
option to slow disease progression and achieve local control, over the years better in-
sight into melanoma biology has taught us which factors can determine the prognosis 
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of each melanoma patient. Treatment options can be tailored based on this. Minimal 
invasive staging procedures continue to be developed, and reconsideration of the ex-
tent of nodal surgery is in place in the light of limited therapeutic eff ect and promising 
adjuvant therapies.
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Summary
This thesis aims to give insight in the current approach to nodal staging of melanoma 
patients in the light of continuing lack of evidence of a therapeutic eff ect from the 
sentinel node biopsy (SNB). This includes reassessment of guideline recommendations 
on SNB regarding thin melanomas, a subgroup at low risk of nodal involvement; and dis-
cussion of potential minimally invasive alternatives for the SNB, including a prospective 
trial protocol (part I). Current practice regarding the timing of elective nodal staging 
surgery is evaluated in the light of a stressed referral system and lack of evidence for a 
highly urgent approach (part II); and fi nally a two-step approach to therapeutic groin 
dissections is presented in order to minimize the number of patients who will undergo 
extensive groin lymph node dissection without having pelvic nodal metastases (part 
III). 
Part I – Nodal Staging
In Chapter 2 the eff ects of implementation of the Dutch Melanoma Guideline 2.0 on 
nodal staging of thin melanomas were investigated, with in particular the new recom-
mendation to consider SNB for high risk thin melanomas, namely pT1B melanomas. 
For this study all newly diagnosed thin (pT1) melanomas between 2003 and 2014 were 
selected from the Netherlands Cancer Registry, in total this concerned near 30,000 
patients. Main fi ndings were that next to a general increase in pT1 melanomas, intro-
duction of the mitotic rate criterion for pT1b substaging and the recommendation to 
perform SNB for pT1b melanoma has led to a proportional increase in pT1b melanomas, 
and an increase in performed SNBs. Sentinel node (SN) positivity rate has not increased 
and survival remained stable for pT1b melanomas, indicating that mitotic rate alone 
as criterion for pT1b has not improved selection of high risk pT1 patients for optional 
further (nodal) staging. Based on the results of this study, recommendations on SNB for 
pT1b melanomas might be reconsidered.
Chapter 3 reports on an ultrasound morphology criterion of the SN, which may add 
to the increased sensitivity and specifi city of preoperative ultrasound assessment of 
clinically nodal negative melanoma patients. In this study 1,000 melanoma patients 
who underwent ultrasound of the SN area prior to a planned SNB at the Charité Univer-
sitätsmedizin Berlin, Berlin, Germany were examined to investigate a new ultrasound 
morphology criterion predictive of SN tumor involvement: “Echo free island” (EFI). Of the 
953 patients in which EFI information was available, EFI was present in 40 patients (4%). 
EFI sensitivity and specifi city were 10.8% and 97.6%, positive and negative predictive 
value were 50% and 80.2%. Presence of EFI was signifi cantly correlated to presence of 
peripheral perfusion, another ultrasound criterion. Five-year melanoma specifi c survival 
(MSS) was worse for patients with EFI: 80% versus 92% when absent. EFI is found to be a 
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discriminatory ultrasound morphology sign which can be useful for early identification 
of sentinel node metastases in melanoma patients. It is an early sign of involvement and 
thus associated with a decreased survival. 
Chapter 4 addresses the long-term results of a potentially minimally invasive alterna-
tive for the SNB. This approach consisting of ultrasound (US) assessment using the Berlin 
morphology criteria and use of fine needle aspiration cytology (FNAC) in case of suspi-
cious or malignant US findings was investigated in 1,000 melanoma patients scheduled 
for SNB at the Charité Universitätsmedizin Berlin, Berlin, Germany. Survival analyses 
demonstrated that patients with positive US-FNAC had poor survival. After adjustment 
for SN status and other known prognostic features, patients with positive US-FNAC had 
worse survival than patients with normal US. Patients with suspicious US and negative 
FNAC and patients with normal US had comparable survival. A step-wise approach to 
melanoma patients is supported by these results: in case of a positive FNAC and/or 
clearly malignant US finding patients can be spared a SNB and be offered a lymphad-
enectomy instead. In case of suspicious US and negative FNAC, patients could be offered 
continue US surveillance or SNB for higher risk primary tumors. Completely US-FNAC 
negative patients might only require follow-up and no SN staging, with continue US 
surveillance as addendum for high risk T3/4 and/or ulcerated primaries.
In Chapter 5 an overview of the literature regarding nodal staging of clinically node 
negative melanoma patients is given, as well as a presentation of a pilot and conse-
quent study protocol for a minimally invasive alternative to the SNB. The literature on 
pre-operative assessment of regional lymph nodes with US in clinically N0 melanoma 
patients is disparate. Targeted US of the SN area in combination with FNAC or other 
new techniques has potential to become a minimally invasive alternative for the SNB, 
however, findings need to be replicated in prospective clinical trials first. A pilot with 
gamma probe guided US-FNAC shows that accurate SN identification in up to 90% of 
patients is feasible. The presented study protocol of the Gamma probe and ULtrasound 
guided Fine needle aspiration cytology of the sentinel node Trial (GULF trial) may pro-
vide potential improvement to the reported US-FNAC techniques and ultimately even a 
possible replacement of the SNB. 
Part II – Timing of SNB and CLND
In Chapter 6 a retrospective series of 1,015 SN positive patients from 9 European Orga-
nization for Research and Treatment of Cancer Melanoma Group Centers is investigated. 
Timing of a SNB after melanoma diagnosis is not associated with 5-year disease free 
survival (DFS) and MSS outcomes. Patients who underwent SNB after a longer time 
interval had a slightly larger SN tumor burden, and although this may have implications 
for prognosis this study did not detect any difference in survival. These findings indicate 
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that it is safe and equally informative to perform SNB after a prolonged interval of >9 
weeks. This information can be used to counsel patients.
Chapter 7 describes the largest SNB population to date to report on the eff ects of SNB 
timing on SN positivity rate and survival. A total of 3,546 patients from 4 European Or-
ganization for Research and Treatment of Cancer Melanoma Group Centers undergoing 
SNB from 1997 – 2013 were selected. No diff erences in survival were found for diff erent 
time interval cut-off s. As expected, a short change in time interval (up to 1 month) has 
no obvious impact on SN positivity rate and prognosis. Whether intervals longer than 3 
months may have an eff ect cannot be determined by this study. This reassuring informa-
tion supports the removal of strict time intervals for wide local excision (WLE) and SNB 
from melanoma guidelines and can be used in daily clinical practice to counsel patients 
and reduce the number of high urgency referrals.
Chapter 8 shows that in a selection of 784 SN positive melanoma patients from the 
cohort described in Chapter 6 with updated follow-up, non-SN positivity and survival 
were not associated with completion lymphadenectomy (CLND) timing. Which indicates 
that it is safe to wait for at least 3 months after diagnosis, as there is no need to perform 
CLND as soon as possible. This information can be used to counsel patients and referring 
physicians and can potentially relieve pressure on the wait list.
Part III – Extent of Lymph Node Dissections in the Groin Area
Chapter 9 provides an accurate two-step approach to predict presence of pelvic nodal 
metastases in patients undergoing therapeutic superfi cial groin dissection. A total of 
209 therapeutic combined groin dissection (CGD) patients from four tertiary centers in 
The Netherlands (1992–2013) were selected based on complete preoperative imaging 
and pathology reports. Combined use of preoperative imaging and a preliminary pre-
diction model based on histopathology results of the inguinal (superfi cial) part of CGD 
could accurately predict negative deep pelvic nodes in up to 84 % of patients, thereby 
potentially identifying a group of low-risk patients in whom the extent of surgery might 
safely be minimized. The risk factors and the prediction model will be further investi-
gated in a prospective, multicenter registry trial for CGDs.
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Samenvatting
Deze thesis bestaat uit 3 delen. In Deel I van deze thesis wordt gepoogd inzicht te geven 
in de benadering van lymfklier stadiering bij melanoompatiënten in het huidige tijdperk, 
gezien het continuerende gebrek aan bewijs voor een therapeutische waarde van de 
schildwachtklier (SWK) procedure. Hieronder valt het herevalueren van aanbevelingen 
in de Nederlandse Melanoom richtlijn ten aanzien van het al dan niet uitvoeren van 
een SWK procedure voor dunne melanomen, een subgroep van patiënten met een laag 
risico op lymfklieruitzaaiingen. Tevens worden potentiele minimaal invasieve alternatie-
ven voor de SWK procedure besproken, waaronder ook een prospectief trial protocol. In 
Deel II worden resultaten uit de huidige klinische praktijk ten aanzien van de timing van 
een SWK procedure geëvalueerd in het kader van overbelaste verwijzingspaden en de 
afwezigheid van wetenschappelijk bewijs voor een hoog urgente aanpak. Deel III om-
vat de presentatie van een 2-staps benadering voor therapeutische liesklierdissecties in 
patiënten met palpabele lymfkliermetastasen in de liesregio ter minimalisatie van het 
aantal negatieve pelviene lymfklierdissecties (afwezigheid van lymfkliermetastasen).
Deel I – Lymfklierstadiering
In Hoofdstuk 2 zijn de eff ecten van implementatie van de Nederlandse Richtlijn Me-
lanoom 2.0 inclusief het gebruik van de 7e editie van het American Joint Committee 
on Cancer Staging System voor dunne melanomen onderzocht. Specifi ek werd hierbij 
gelet op de toegevoegde aanbeveling om een SWK te overwegen bij hoog risico dunne 
melanomen (pT1b). Voor deze studie werden alle nieuw gediagnosticeerde pT1 melano-
men tussen 2003 en 2014 geselecteerd uit de Nederlandse Kankerregistratie, in totaal 
betrof het bijna 30,000 patiënten. De voornaamste bevindingen waren dat, naast een 
algemene stijging van het aantal pT1 melanomen, het aantal pT1b melanomen propor-
tioneel steeg na introductie van het mitose index criterium voor de pT1b classifi catie in 
de nieuwe richtlijn. Tevens steeg het aantal uitgevoerde SWK procedures. De proportie 
positieve SWK’s is niet gestegen, en overleving is stabiel gebleven voor pT1b melanomen. 
Dit wijst uit dat het mitose index criterium voor de classifi catie als pT1b melanoom geen 
verbeterde selectie van hoog risico pT1 melanomen voor eventuele verdere (lymfklier)
stadiering teweeg heeft gebracht. Aanbevelingen over een SWK procedure voor pT1b 
melanomen zouden kunnen worden herzien op basis van de resultaten van deze studie.
Hoofdstuk 3 beschrijft een nieuw echografi e morfologie criterium voor de SWK, het 
“echo free island” (EFI) welke mogelijk kan bijdragen aan een verhoogde sensitiviteit 
en specifi citeit van preoperatieve echografi e bij klinisch lymfklier negatieve mela-
noompatiënten. In deze studie zijn 1.000 melanoompatiënten geïncludeerd die een 
preoperatieve echografi e van het SWK gebied ondergingen voorafgaand aan een SWK 
procedure in het Charité Universitätsmedizin Berlin, Berlijn, Duitsland. EFI was aanwezig 
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in 40 patiënten (4%) van de 953 patiënten waarbij EFI informatie beschikbaar was. EFI 
sensitiviteit en specificiteit voor aanwezigheid van SWK metastasen waren 10.8% en 
97.6%, positief en negatief voorspellende waarde waren 50% en 80.2%. De aanwezig-
heid van EFI was significant gecorreleerd met aanwezigheid van perifere perfusie, een 
ander echografie criterium. Vijf-jaars melanoom specifieke overleving was slechter voor 
patiënten met EFI: 80% versus 92% in afwezigheid van EFI. Concluderend is EFI een goed 
te onderscheiden echografie morfologiekenmerk dat behulpzaam kan zijn voor vroege 
identificatie van SWK metastasen in melanoompatiënten. Het is een vroeg teken van 
SWK betrokkenheid en daarmee geassocieerd met een lager overlevingspercentage. 
Hoofdstuk 4 spitst zich toe op de lange termijn resultaten van een potentieel mini-
maal invasief alternatief voor de SWK procedure. Het gaat hierbij om echografie met 
gebruik van de Berlin morfologie criteria en het gebruik van een dunne naald cytolo-
gische punctie (fine needle aspiration cytology, FNAC) in het geval van een verdacht of 
evident maligne ogende echobevinding van de SWK. Deze procedure is onderzocht in 
meer dan 1.000 melanoompatiënten die een geplande SWK procedure ondergingen het 
Charité Universitätsmedizin Berlin, Berlijn, Duitsland. Analyse van de overlevingsdata 
toonde dat patiënten met positieve echo en/of FNAC een slechte overleving hadden. 
Na correctie voor SWK status en andere bekende prognostische kenmerken hadden 
patiënten met positieve echo/FNAC nog steeds een slechtere overleving dan patiënten 
met een normale echo uitslag. Patiënten met een verdachte echo uitslag en negatieve 
FNAC en patiënten met een normale echo uitslag hadden een vergelijkbare overleving. 
Deze resultaten ondersteunen een stapsgewijze aanpak voor melanoompatiënten: bij 
een positieve FNAC en/of duidelijk maligne echo uitslag kan een SWK procedure ach-
terwege blijven en direct een complete lymfklierdissectie worden aangeboden. In het 
geval van een verdachte echo uitslag en negatieve FNAC kan echografische follow-up 
of een SWK procedure worden aangeboden voor hoog risico melanomen. Bij echo en 
FNAC volledig negatieve patiënten kan overwogen worden om alleen follow-up uit te 
voeren zonder SWK stagering, met als aanvulling regelmatige echografie bij hoog risico 
T3/T4 of ge-ulcereerde melanomen. 
In Hoofdstuk 5 wordt een overzicht van de literatuur gegeven over de lymfkliersta-
diering van klinisch lymfklier negatieve melanoompatiënten, alsmede een presentatie 
van een studie pilot en bijbehorend aanvullend studieprotocol voor een minimaal 
invasief alternatief voor de SWK. De literatuur over preoperatieve beoordeling van 
regionale lymfklieren met echografie in klinisch lymfklier negatieve melanoompatiënt is 
uiteenlopend. Gerichte echografie van het SWK gebied in combinatie met FNAC of an-
dere nieuwe technieken heeft potentie om een minimaal invasief alternatief te vormen 
voor de SWK procedure, echter moeten deze resultaten tot op heden nog gerepliceerd 
worden in prospectieve klinische trials. De uitgevoerde pilot studie met gamma-probe 
geleide echografie en FNAC van de SWK laat zien dat hiermee correcte SWK identificatie 
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in 90% van de patiënten uitvoerbaar is. Het gepresenteerde studieprotocol van de 
gamma probe en echografi sch geleide FNAC van de SWK trial (GULF trial) kan mogelijk 
bijdragen aan een verbetering van de reeds gerapporteerde echo/FNAC technieken en 
uiteindelijk eventueel een vervanging zijn voor de SWK procedure. 
Deel II – Timing van SWK en completerende lymfklierdissectie
Hoofdstuk 6 beschrijft een retrospectief cohort van 1.015 SWK positieve patiënten 
uit 9 European Organization for Research and Treatment of Cancer Melanoma Group 
(EORTC-MG) centra. In dit cohort werden de eff ecten van timing van de SWK procedure 
na melanoomdiagnose op ziektevrije en ziekte specifi eke overleving onderzocht. De 
timing van een SWK procedure is niet geassocieerd met 5-jaars ziektevrije of ziekte 
specifi eke overleving. Patiënten die een langer tijdsinterval hadden tussen diagnose en 
SWK procedure hadden een minimaal hogere SWK tumor grootte, en hoewel dit impli-
caties kan hebben voor de prognose liet deze studie geen verschil in overleving zien. 
Deze resultaten indiceren dat het veilig is en even informatief om een SWK procedure 
te verrichten na een langer tijdsinterval van > 9 weken. Deze informatie kan gebruikt 
worden om patiënten te adviseren. 
Hoofdstuk 7 beschrijft de resultaten van de grootste SWK populatie tot op heden 
waarbij de eff ecten van SWK procedure timing op SWK uitslag en overleving zijn 
onderzocht. In totaal werden 3.546 patiënten geselecteerd die een SWK procedure 
ondergingen tussen 1997 – 2013 in 4 EORTC-MG centra. Er werden geen verschillen in 
overleving gevonden voor verschillende tijdsinterval afkapwaarden. Zoals te verwach-
ten heeft een korte variatie in tijdsinterval tussen diagnose en SWK-procedure (tot 1 
maand) geen duidelijke invloed op de kans op een positieve SWK en prognose. Of een 
interval van meer dan 3 maanden een dergelijk eff ect heeft kan niet worden bepaald op 
basis van deze studie. Deze geruststellende resultaten ondersteunen de verwijdering 
van strikte tijdslimieten voor re-excisie en SWK-procedures uit melanoom richtlijnen. 
Daarnaast kan deze informatie in de dagelijkse praktijk worden toegepast om patiënten 
te adviseren en het aantal hoog urgente verwijzingen te minimaliseren. 
Hoofdstuk 8 laat zien dat in een selectie van 784 SWK positieve patiënten met 
aangevulde follow-up gegevens uit het cohort beschreven in Hoofdstuk 6 er geen 
associatie werd aangetoond tussen timing van een completerende lymfklierdissectie 
en aanvullende positieve lymfklieren of overleving. Dit indiceert dat het veilig is om mi-
nimaal 3 maanden te wachten met een lymfklierdissectie na diagnose van het primaire 
melanoom, aangezien er in het licht van deze resultaten geen noodzaak is om deze 
operatie zo snel mogelijk uit te voeren. Deze informatie is bruikbaar voor het adviseren 
van zowel patiënten als verwijzende artsen, en kan mogelijk zorgen voor een daling van 
de druk op de wachtlijst. 
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Deel III – Uitgebreidheid van lymfklierdissecties in de liesregio 
Hoofdstuk 9 geeft een accurate twee-staps benadering weer om aanwezigheid van pel-
viene lymfkliermetastasen te voorspellen in patiënten die een therapeutische inguinale 
(oppervlakkige) lymfklierdissectie ondergaan. Voor deze studie werden 209 patiënten 
met een therapeutische ilio-inguinale (oppervlakkige en diepe) lymfklierdissectie tus-
sen 1992-2013 geselecteerd uit 4 tertiaire melanoomcentra in Nederland, gebaseerd 
op aanwezigheid van preoperatieve beeldvorming en adequate pathologieverslagen. 
Gecombineerd gebruik van preoperatieve beeldvorming ter uitsluiting van pelviene 
lymfkliermetastasen en een preliminair predictiemodel gebaseerd op pathologieresul-
taten van de inguinale lymfklierdissectie leidde tot accurate predictie van negatieve 
pelviene lymfklieren in 84% van de patiënten. Hiermee kan potentieel een laag risico 
groep patiënten worden geïdentificeerd waarbij de uitgebreidheid van de lymfklierdis-
sectie veilig geminimaliseerd kan worden. De risicofactoren en het predictiemodel 
zullen verder onderzocht moeten worden in een prospectieve multicenter registratie 
trial voor patiënten die een ilio-inguinale lymfklierdissectie ondergaan. 
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Summary of PhD training and teaching activities
Name PhD student:
Charlotte Maria Catharina Oude Ophuis, MD
Erasmus MC Department:
Surgery, Division of Surgical Oncology
Research School:
Medicine
PhD period:
September 2014 – September 2016
Promotor:
Prof. dr. C. Verhoef, MD PhD
Supervisors:
Dr. D.J. Grünhagen, MD PhD
Dr. A.C.J. van Akkooi, MD PhD
1. PhD training
Year Workload
(Hours/ECTS)
General academic skills 
- Research Integrity 2015 0.5 
-  Basiscursus Regelgeving en Organisatie Klinisch Onderzoekers (BROK) 2015 1.5 
Research skills
- Open Clinica Course 2015 0.5 
- Systematic Literature Retrieval Course 2015 0.5 
Oral Presentations
- 37th ISDS meeting, Amsterdam, the Netherlands 2016 1 
- ISNS 2016 biannual meeting, Milan, Italy 2016 1 
- EORTC MG spring meeting, Milan Italy 2016 1 
- EORTC MG fall meeting, Berlin, Germany 2016 1 
- 18th ECCO – 40th ESMO Congress, Vienna, Austria 2015 1 
- 68th SSO meeting, Houston, Texas, USA 2015 1 
- EORTC MG fall meeting, Rotterdam, the Netherlands 2015 1 
- 34th ESSO-BASO congress, Liverpool, United Kingdom 2014 1 
- Annual Melanoma Congress 2014, Paris, France 2014 1 
- Chirurgendagen 2015 NVVH, Veldhoven, the Netherlands 2014 1 
- EORTC MG spring meeting, London, United Kingdom 2014 1 
Poster Presentations
- 70th SSO meeting, Seattle, Washington, USA 2017 0.5 
- ECCO 2017, Amsterdam, the Netherlands 2017 0.5 
- 69th SSO meeting, Boston, Massachusetts, USA 2016 0.5 
- Annual Melanoma Congress 2014, Paris, France 2014 0.5 
- Najaarsdag NVVH, Den Bosch, the Netherlands 2013 0.5 
International Conferences
- ECCO 2017, Amsterdam, the Netherlands 2017 1 
- 37th ISDS meeting, Amsterdam, the Netherlands 2016 0.5 
- ISNS 2016 biannual meeting, Milan, Italy 2016 1 
- EORTC MG spring meeting, Milan Italy 2016 0.5 
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- EORTC MG fall meeting, Berlin, Germany 2015 1 
- 18th ECCO – 40th ESMO Congress, Vienna, Austria 2015 2 
- 68th SSO meeting, Houston, Texas, USA 2015 1.5 
- EORTC MG fall meeting, Rotterdam, the Netherlands 2014 1 
- 34th ESSO-BASO congress, Liverpool, United Kingdom 2014 2 
- Annual Melanoma Congress 2014, Paris, France 2014 1 
- EORTC MG spring meeting, London, United Kingdom 2014 1 
2. Teaching activities
Year Workload (Hours/
ECTS)
Supervising practicals and excursions
- Basic Life Support examinator medical students 2015 - 2016 0.5
Supervising Master students
- Supervision master students extracurricular research 2016 3 
Other
- Supervisor Kennismaking Beroepspraktijk (KBP) 2016 0.5 
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Dit proefschrift zou er niet geweest zijn zonder de steun en het vertrouwen van alle 
mensen om mij heen, waarvoor ontzettend veel dank! Een aantal mensen wil ik hierbij 
in het bijzonder bedanken.
Mijn hooggeleerde promotor Prof. dr. C. Verhoef, beste Kees, het was een voorrecht 
om onder jouw hoede onderzoek te doen in de Daniel. Alles begon ooit als een extra 
tijdverdrijf naast het SOG-en in de kliniek, maar leidde toch zomaar tot dit boekje. Dit is 
denk ik vooral te danken aan jouw onvermoeibare vertrouwen dat alles toch wel goed 
zou komen. Af en toe alleen een brul over de gang; “werken!”, want dat doen de onder-
zoekers van A1 natuurlijk veel te weinig naar jouw idee.  Haast onmerkbaar legde jij de 
lat voor mij steeds een stukje hoger, met goed resultaat. Dank voor alle uitdagingen, 
aanmoedigingen en steun, een betere baas kan ik me niet voorstellen! After all, time is 
on our side ;)!
Mijn hooggeachte copromotor Dr. D.J. Grünhagen, beste Dirk, zo ontzettend enthousi-
ast als jij kan zijn is werkelijk uniek. Ik heb genoten van onze discussies over van alles en 
nog wat, vele contacten vlak voor deadlines en de mooie momenten als we weer een 
subsidie binnengehaald hadden. Dank voor alle duwtjes in de goede richting! Ik hoop 
dat ik nog veel van je mag leren.
Mijn hooggeachte copromotor Dr. A.C.J. van Akkooi, beste Alex, wat een voorganger 
op melanomengebied! In jouw voetsporen mogen treden was een waar avontuur en 
een eer, met alle kennis en netwerken die je om je heen hebt verzameld. Fantastisch dat 
je me mee op sleeptouw nam naar alle congressen, en ontzettend veel dank voor al je 
support. Als ik ooit weer een vraag heb over melanomen weet ik waar ik moet zijn! 
Hooggeleerde leden van de leescommissie, Prof. dr. S. Sleijfer, Prof. dr. T. Nijsten, Prof. dr. 
H.J. Hoekstra, hartelijk dank voor het lezen en positief beoordelen van mijn proefschrift.
Dear coauthors, dear members of the EORTC Melanoma Group, thank you very much for 
the great collaboration on some of the papers in this thesis, it meant a great deal to me 
to have your support! I hope we meet again in the future. 
Leden van het GULF team, Dr. L.B. Koppert, Dr. C. de Monyé, Dr. C.H.M. van Deurzen, Dr. 
S. Koljenovic, en bovengenoemde heren, beste Linetta, Cécile, Carolien, en Senada, het 
was een waar avontuur om samen met jullie de GULF trial op te zetten. Ontzettend veel 
dank voor alle steun en betrokkenheid!
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Chirurgen van de Daniel, ook jullie kan ik niet ongenoemd laten; de vele lunches inclusief 
pindasoep en saus, doordrenkt met foute grappen, waren een heerlijke onderbreking 
van het cijfertjes en lettertjes kijken. Hopelijk tot ziens aan de andere kant van de Maas!
Beste maatjes van het onderzoek, beste Victorien, Wijnand, Eric, Danique, Elvira, Thijs, 
Boris, Melissa, Maarten en co, ik heb een top tijd met jullie beleefd! Ook al was er nogal 
eens gesteggel over wie er nu weer croissants moest halen voor de early bird, of wie 
het laatste nespresso cupje had opgemaakt, de vele koffiepauzes en barbeques op ons 
dakterras maakten alles goed. Zonder jullie om me heen was dit boekje er nog lang niet 
geweest. Keep the spirit going!
Dear Asha, thank you for the opportunity to collaborate on some of you papers, I admire 
your enthousiasm. Hope you are doing well, we will meet again!
Beste Max, ook jij bedankt voor de hulp met alle data en het schrijven, maar vooral 
natuurlijk de mental support als we weer eens mochten presenteren voor de EORTC en 
daarna op culturele ontdekkingstocht gingen op zoek naar de lokale drankjes. Veel suc-
ces met je boekje en je opleiding, ik zie je wel weer op een volgende cursus of congres!
Lieve clubgenoten, ploeggenoten, geneeskundebuddies, huisgenoten en andere vrien-
den, jullie zorgden voor de broodnodige afleiding de afgelopen jaren. Dank daarvoor! 
Lieve JC pitch, lieve clubgenootjes, dank voor alle heerlijke etentjes en wijntjes als ik 
weer eens een deadline op het nippertje had gehaald, of weer iets nieuws op mijn bord 
geschoteld kreeg, en dank voor alle begrip als ik ergens weer niet bij kon zijn. Dat er nog 
maar vele mooie herinneringen mogen volgen!
Lieve Clubdames, weer eentje die eindelijk klaar is met haar onderzoek! Dank voor 
alle lieve woorden als het even tegen zat, en natuurlijk alle mooie borrels, feestjes en 
weekendjes samen. Ik houd mijn agenda vrij voor alle komende borrels! En volgend jaar 
de Ringvaart toch??!
Lieve Spetters, zo fijn om jullie nog steeds te zien na al die jaren in Groningen! Roeien 
zal hem niet meer worden, maar het alternatief (lekker borrelen) vindt ik helemaal prima! 
Dank voor alle steun en we zien elkaar snel weer ergens in NL of Engeland.
Lieve Maasdames, ik ben zo blij dat ik samen met jullie mag roeien op de Rotte! Een 
heerlijke uitlaatklep voor alle onderzoeks- en werkstress, en wat gaan die halen lekker! 
Ik hoop op nog veel kilometers samen op de Rotte en op andere wateren, en daarnaast 
natuurlijk ook veel mooie drankjes @ de Maas en elders. 
Lieve Lisanne Rigter, wat fijn om nog een lotgenootje te hebben in het onderzoeksleven. 
Ik vond het erg gezellig om af en toe bij jou op de kamer aan de slag te gaan! Heel veel 
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succes met je eigen boekje, dat wordt vast prachtig! We spreken snel weer eens af in 010 
of 020. 
Lieve paranimfj es, Esther en Mirelle, de keuze was snel gemaakt wie mij mogen verge-
zellen als mentale en fysieke support tijdens mijn verdediging. 
Lieve Esther, zonder jouw toevallige ontmoeting met onderzoek was ik misschien wel 
nooit gaan promoveren. Wat een tijd was dat, zwoegen aan ons eerste artikel met thee 
en chocola (want daar gaan je hersenen harder van werken, hè Es?). Maar gelukkig was 
er ook tijd om te investeren in onze kookkunsten en smaakpapillen voor lekkere wijn-
tjes. Je bent en blijft mijn steun en toeverlaat. Ik hoop dat we samen nog vele avonturen 
zullen beleven! 
Lieve Mirelle, wat een zegen dat jij een groot bureau nodig had voor al je fancy 
beeldschermen! Daardoor heb ik een topper als kamergenootje gehad, je hebt me er 
doorheen gesleept met je onvermoeibare energie en tijd om te overleggen als ik weer 
ergens op vastliep. Wat hebben we veel afgekletst, en nee niet over mooie mannen maar 
over kaplan meiers en regressieanalyses, heel sexy… Gelukkig konden we de schade 
altijd inhalen buiten de Daniel met een biertje erbij. Heel veel succes met de laatste 
loodjes, en je weet het he, unicorns can fl y!
Lieve schoonfamilie, lieve Tjeerd Frans, Geertje, Teun en Laura, 
Ik had me geen betere tweede familie kunnen wensen. Altijd hebben jullie mij gesteund 
en geholpen als ik weer eens met mijn laptop aan kwam zetten, of last minute iets moest 
printen. Dank voor jullie eeuwige geduld en bemoedigende woorden. Ik heb genoten 
van alle keren dat we lekker zijn gaan zeilen en borrelen, of gewoon lekker uitwaaien in 
Oostmahorn. En natuurlijk niet te vergeten al de “heerlijke avondjes” met pittige gedich-
ten. Ik wens jullie alle goeds toe en hoop op nog vele mooie jaren samen!
Lieve broertjes, 
Lieve Roderik (Rook), mijn grote kleine broer, dank dat je er altijd bent geweest en voor 
me klaar staat. Dank ook voor het helpen relativeren; er zijn gelukkig ook nog dingen 
buiten onderzoek en het ziekenhuis. Ik geniet ervan om te zien hoe gemakkelijk jij je 
weg vormt en van het leven geniet; eerst binnen je studie en nu bij je eerste baan. Ik 
weet zeker dat je het nog ver zult schoppen! 
Lieve Sebastiaan (Sebas), ook al zo’n grote kleine broer, ook jij zorgt ervoor dat ik weet 
dat er meer in het leven is dan alleen maar werk. Dank voor al je heerlijk onbezorgde 
vragen. Ik ben zo trots op je dat je door blijft zetten om de studie te doen die je leuk 
vindt, ondanks alle tegenslagen. Ook jij gaat nog een hele mooie toekomst tegemoet. 
Ik houd van jullie, lieve broertjes, en ik hoop dat we samen nog veel mooie dingen zullen 
meemaken.
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Lieve papa en mama, 
Door jullie oneindige steun en liefde, en bemoedigende woorden ben ik uiteindelijk 
zover gekomen dat ook mijn boekje nu klaar is. Ik weet niet waar ik moet beginnen jullie 
te bedanken. Papa, voor alle opbeurende kritiek als ik het niet meer zag zitten, mama, 
voor je luisterend oor en begrip. Dankjewel ook voor alle hulp bij statistische problemen 
en voor je mooie aquarel voor de voorkant. Ik ben zo trots op jullie! Nog een hele mooie 
toekomst samen!
Lieve lieve Frans,
Jij hebt de zwaarste last gedragen van iedereen, en hoe! Ik kan onmogelijk in woorden 
uitleggen hoeveel je me hebt geholpen de afgelopen jaren. Je hebt me in alles gesteund, 
en gezorgd voor afleiding wanneer het nodig was. Je hebt me erdoorheen gesleept, en 
ik kan me niet bedenken wat ik zonder jou zou moeten. Lieverd, ik houd van jou, en ik 
beloof je dat we vanaf nu nog veel meer gaan genieten van het leven!
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 Curriculum vitae
Charlotte Maria Catharina Oude Ophuis, auteur van dit proefschrift, werd geboren 
op 9 december 1988 te Wageningen. Aldaar groeide zij op en behaalde in 2006 cum 
laude het eindexamen Gymnasium aan de Regionale Scholengemeenschap Pantarijn. 
Hetzelfde jaar begon zij aan de studie Geneeskunde in Groningen. Al tijdens het eerste 
jaar van haar studie raakte zij betrokken met het doen van wetenschappelijk onderzoek, 
eerst in het kader van de Junior Scientifi c Masterclass, en later extracurriculair op de 
afdeling Neurochirurgie van het Universitair Medisch Centrum Groningen (UMCG). Hier 
verrichte zij ook haar wetenschappelijke stage, voorafgaand aan haar coschappen in 
het UMCG en de Isala Klinieken te Zwolle. De laatste 2 maanden van haar coschappen 
voltooide zij op de afdeling Transplantatiechirurgie van het Mount Sinai Hospital te New 
York, New York, USA. In maart 2013 behaalde zij cum laude haar artsexamen, en in mei 
2013 begon als zij arts-assistent bij de Snijdende Oncologische Groep in de Daniel den 
Hoed Kliniek. Alhier startte zij onder begeleiding van Prof. dr. C. Verhoef, Dr. D.J. Grün-
hagen en Dr. A.C.J. van Akkooi een onderzoek naar stadium III melanomen. Hiermee 
werd de basis gelegd voor meerdere studies welke hebben geleid tot dit proefschrift. 
Tijdens haar onderzoeksperiode heeft Charlotte meerdere voordrachten gehouden op 
internationale congressen met multipele nominaties en in 2015 de toekenning Best Ab-
stract op het 18e ECCO – 40e ESMO Congres in Wenen. Tevens heeft zij een prospectieve 
studie opgezet, de GULF trial, welke momenteel loopt in het Erasmus Medisch Centrum 
Kankerinstituut (voorheen Daniel den Hoed Kliniek) en het Nederlands Kankerinstituut 
– Antoni van Leeuwenhoek. Per 1 oktober 2016 is zij gestart als arts-assistent chirurgie in 
het Maasstad Ziekenhuis te Rotterdam, waar zij per 1 juli 2017 tevens is begonnen met 
de opleiding Heelkunde. Op 2 juni 2017 is zij getrouwd met Frans Gysolt Smits met wie 
zij gelukkig samenwoont in Rotterdam.
